Modern Pharma - 1-15 April 2013 by Infomedia18

1 - 15 A p r i l 2 013 I Vo l 1 I N o 19 I ` 10 0

www.modernpharma.in

Scan this code on your smart phone to visit www.modernpharma.in

In Conversation With 12

Special Focus 14

Facility Visit 20

Event Report 25

Nathan Sigworth Co-Founder and CEO, Pharmasecure

Contract manufacturing Offering cost-effective solutions amid uncertain economic scenario

Venus Remedies, Baddi Riding high on innovation

8th Nutra INDIA Summit

Baxter closes deal for potential haemophilia drug Baxter International Inc has closed its acquisition of a potential haemophilia treatment from the French drug maker Ipsen and Inspiration Biopharmaceuticals Inc. in a deal that could be worth more than $ 180 million. Baxter, based in Deerfield, Ill, had said in January it agreed to buy the drug, labeled OBI-1, and related manufacturing operations. Ipsen announced that Baxter agreed to pay $ 50 million upfront, up to $ 135 million in milestone payments and a percentage of global sales. OBI-1 is being studied as a possible treatment for people with acquired haemophilia A. OBI-1 has been designated an orphan drug in the United States and the European Union, meaning it will get years of marketing exclusivity if it is approved.

Avastin unit dose syringes recalled due to potential eye infection Clinical Specialties is voluntarily recalling Avastin unit dose syringes. The product has or potentially could result in an infection within the eye. Clinical Specialties has received reports of five intra-ocular infections from physician’s office and this is how the problem was identified. The product was being used solely as an off-label use by ophthalmologists for macular degeneration and is packaged in sterile syringes.

Venus launches its ﬁrst OTC product Ezenus Venus Remedies Ltd recently announced the launch of its first OTC product EZENUS, a stress reliever. While introducing this product, Dr (Mrs) Manu Chaudhary, Joint Managing Director, Venus Remedies Ltd, said, “EZENUS is a unique medical nutrition product which is absolutely safe, zero calorie, non–addictive, herbal candy, with clinically proven anti-stress activity. It is world’s first anti-stress product launched in easy to use candy form even suitable for diabetic patients. It is highly safe in acute stress management such as exam stress in children and in chronic stress like in alcoholic and smoking population, without change in life style by continuous detoxification and strong antioxidant activity.” EZENUS is a patent protected herbal, anti-stress formulation based on German Technology.

Providing impetus to the surging nutraceutical market

Dr Kallam Anji Reddy passes away Dr K Anji Reddy, Founder and Chairman of Dr. Reddy’s Laboratories Ltd, recently passed away of liver cancer at the Apollo Hospital in Hyderabad. He was considered as the drug discovery pioneer in pharmaceutical industry. His mission in life was to provide innovative new medicines at a price that the common man could afford. Dr Reddy obtained graduation from University of Mumbai with specialisation in Pharmaceutical Science and Fine Chemicals and later PhD in Chemical Engineering from National Chemical Laboratory, Pune.

Dr Reddy

Soon after his studies, he served in the state-owned IDPL before he founded the company in 1984. He was honoured by the Government of India with the Padma Bhushan, one of the highest Civilian Awards in India, recognising his distinguished service of high order in the field of Trade and Industry. In 2012, CNBC TV18 conferred the Lifetime Achievement Award (IBLA) on him for being a visionary who had spent a lifetime building up his company into a colossus with a global reach putting Indian industry on the world map.

Waters releases new products in the analytical standards and reagents portfolio Waters Corporation has introduced Quality Control Reference Materials (QCRMs) and certified containers for the analytical standards and reagents product group. Designed for Waters instruments, QCRMs are the simplest and fastest way to understand a chromatography or MS system’s health while ensuring repeatable performances. Waters certified containers for solvents and mobile phases are uniquely processed and treated to prevent extraneous peaks and baseline noise. The new certified containers help ensure that our customers can produce dependable, consistent and high quality results as easily as possible. Manufactured to stringent standards, these unique

containers prevent extraneous peaks and baseline noise, glass chemistry interference and glass degradation

due to glass matrix hydrolytic attack. “We added analytical standards and reagents to Waters’ competency because they improve the accuracy of measurements. QCRMs and certified containers are another significant and innovative step in that direction. By integrating these products, customers can see improved data acceptance. Furthermore, by eliminating the need to mix and formulate standards and the unknown quality of mobile phase and solvent containers, our customers will have more time for scientific problem solving,” said Mike Yelle, Vice President, Consumable Business Unit, Waters.

Utkarsh Palnitkar joins KPMG as the National Head of Transactions & Restructuring and Life sciences practices Utkarsh Palnitkar has joined KPMG India as Partner & National Head of Transactions & Restructuring and Life sciences practices. Palnitkar joins KPMG from Centrum Capital Ltd, a large financial services company, where he was an Executive Director. Prior to this, he was associated with Ernst & Young (E&Y) for 15 years. During this period, he was the leader of Advisory as well as the Life sciences practice, while also being the office managing partner of E&Y’s Hyderabad practice. He

was engaged in transaction advisory services, business advisory services and risk advisory services. Speaking on the appointment, Richard Rekhy, CEO, KPMG India, said, “We are delighted to welcome Palnitkar into the KPMG family. An industry veteran, Palnitkar has a vast experience across life sciences,

business advisory, government, real estate and infrastructure advisory. I am confident that under his able leadership, the Transactions & Restructuring business will see exponential growth in the coming phase.” Palnitkar is a Chartered Accountant from the Institute of Chartered Accountants of India. In addition, he has completed an Advanced Management Program - Harvard Business School and Leadership Programs from Indian School of Business.

0RGHUQ 3KDUPD $SULO

CONTENTS In Conversation With

In Conversation With: Nathan Sigworth Co-Founder and CEO, Pharmasecure

Special Focus Pharma Manufacturing Contract manufacturing Offering cost-effective solutions amid uncertain economic scenario

Green manufacturing practices Sustainable solutions to drive the future economy

Interface Sunil Aggarwal Director, Airtech Systems India Pvt Ltd

Facility Visit Venus Remedies Ltd, Baddi Riding high on innovation

www.modernpharma.in

20 FOUNDER & EDITOR, NETWORK 18 Raghav Bahl PRESIDENT & EDITORIAL DIRECTOR, TV 18 Senthil Chengalvarayan

Insight & Outlook

SENIOR EDITOR Manas R Bastia EDITORIAL TEAM Parita Dholakia, Pallavi Mukhopadhyay, Rishab Kothari, Hardik Ashar (Bengaluru), Nikunj Sharma (Delhi)

Interface Prof Ranjit Roy Chaudhury Chairman - Task Force for Research, Apollo Hospitals Educational and Research Foundations

ART DIRECTOR Varuna Naik DESIGN Varghees Tharakan CHIEF PHOTOGRAPHER Mexy Xavier PHOTOGRAPHY Neha Mithbawkar, Joshua Navalkar, Nachiket Gujar

Event Report 8th Nutra India Summit Providing impetus to the surging nutraceutical market

BUSINESS CONTROLLERS Surekha Karmarkar, Lovey Fernandes, Akshata Rane, Deepak Bhatia, Ashish Kukreti, Shwetha ME, Jayashree N, Sugandha Kulkarni, Shefali Mahant

PRINTING EXECUTIVE VICE PRESIDENT Ananth R Iyer ASSISTANT GENERAL MANAGER - PPC Shekhar Khot

REGULAR SECTIONS 5 Editorial / Guest Editorial

PRODUCTION TEAM

Surekha Karmarkar, Ravikumar Potdar, Ravi Salian, Sanjay Shelar

OVERSEAS CONTACT CHINA 1001 Tower 3, Donghai Plaza, 1486 Nanjing Road, West, Shanghai 200040, China Tel: +86-21 6289 – 5533 Ext. 368, Fax: +86-21 6247 – 4855 (Craig Shibinsky) Email: craig@ringier.com.hk Ringier Trade Media Ltd HONG KONG 9/F, Cheong Sun Tower, 118 Wing Lok Street, Sheung Wan, Hong Kong Tel: +852 2369 – 8788 Ext. 21, Fax: +852 2869 – 5919 (Octavia Au-Yeung) Email: octavia@ringier.com.hk Ringier Trade Media Ltd TAIWAN Room 3, Fl. 12, No. 303, Chung Ming S. Rd., Taichung, Taiwan Tel: +886-4 2329 – 7318 Ext. 16, Fax: +886-4 2310 – 7167 (Sydney La) Email: sydneylai@ringier.com.hk Ringier Trade Media Ltd GERMANY, AUSTRIA, SWITZERLAND Tel: +41-44 734 0472, Fax: +41 44 734 0680 Email: info@islerannoncen.ch Ringier Trade Media Ltd

6 News, Views & Analysis 22 Projects 23 Tenders 24 Event List 26 Book Review 27 Products 29 Marketplace 30 List of Products & Advertisers

USA Tel: (513) 527-8800 Fax: (513) 527-8801 Email: dhight@gardnerweb.com USA Alfredo Domador, 6505 Blue Lagoon Drive, Suite 430 Miami, FL. 33126, USA Tel: (305) 448-6875, Fax: (305) 448-9942

GROUP CEO, NETWORK 18 B Sai Kumar CEO-NETWORK 18 PUBLISHING Sandeep Khosla EVP-HUMAN RESOURCES Sanjeev Kumar Singh ASSOCIATE VICE PRESIDENT Sudhanva Jategaonkar ADVERTISING SALES Shashin Bhagat (Ahmedabad) shashin.bhagat@network18publishing.com Mahadev B (Bengaluru) mahadev.b@network18publishing.com Hari Hara Subramaniam (Chennai) hari.s@network18publishing.com Balakrishnan S (Coimbatore) balakrishnan.s@network18publishing.com Surendra Agarwal (Delhi) Surendra.a@network18publishing.com Dominic Dsouza (Hyderabad) dominic.dsouza@network18publishing.com Ameya Gokhale (Indore) ameya.gokhale@network18publishing.com Sandeep Arora (Jaipur) sandeep.arora@network18publishing.com Abhik Ghosal (Kolkata) abhik.ghosal@network18publishing.com Inder Dhingra (Ludhiana) inder.dhingra@network18publishing.com Surajit Bhattacharjee surajit.b@network18publishing.com Olwin Dsouza (Mumbai) olwin.dsouza@network18publishing.com Rohit Dass (Pune) rohit.dass@network18publishing.com Vipul Modha (Rajkot) vipul.modha@network18publishing.com Chirag Pathak (Vadodara) chirag.pathak@network18publishing.com MARKETING TEAM Ganesh Mahale, Akshaya Jadhav

NEWSSTAND AND SUBSCRIPTIONS

DISTRIBUTION HEAD Sunil Nair DEPUTY GENERAL MANAGER Manoj Palsay SENIOR MANAGER - SUBSCRIPTIONS Sheetal Kotawdekar CO-ORDINATORS Rahul Mankar, Anant Shirke, Sarita Quadros, Chaitali Parkar, Kamlesh Mathkar, Vaibhav Ghavale

SERVICES

SUBSCRIPTION SERVICES For subscription queries, write to chaitali.parkar@network18publishing.com or call +91 22 30034631-34 or toll free 1800 200 1021 PERMISSIONS

For subscription to copy or reuse material from Modern Pharma, Write to spedit@network18publishing.com )RUWQLJKWO\ ,VVXH 3ULFH ` 100 $QQXDO 6XEVFULSWLRQ ` 1200

Views and opinions expressed in this magazine are not necessarily those of Network18 Media & Investments Ltd (Network18)*, its publisher and/or editors. We at Network18 do our best to verify the information published but do not take any responsibility for the absolute accuracy of the information. Network18 does not accept the responsibility for any investment or other decision taken by readers on the basis of information provided herein. Network18 does not take responsibility for returning unsolicited material sent without due postal stamps for return postage. No part of this magazine can be reproduced without the prior written permission of the publisher. Network18 reserves the right to use the information published herein in any manner whatsoever.

Highlights of Next Edition Special Focus: Quality compliance - GMP, GLP, GDP Note: ` stands for Indian rupee, $ stands for US dollar and £ stands for UK pound, unless mentioned otherwise

Printed by Mohan Gajria and published by Lakshmi Narasimhan on behalf of Network18. Senior Editor: Manas R Bastia Printed at Infomedia 18 Ltd, Plot no.3, Sector 7, off Sion-Panvel Road, Nerul, Navi Mumbai 400 706, and published at Network18, ‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W), Mumbai - 400 028. Modern Pharma is registered with the Registrar of Newspapers of India under No. MAHENG / 2008 / 27125. Network18 does not take any responsibility for loss or damage incurred or suffered by any subscriber of this magazine as a result of his/her accepting any invitation/offer published in this edition. *Ownership of this magazine stands transferred from Infomedia18 Ltd (Infomedia18) to Network18 Media & Investments Ltd (Network18) in pursuance of the scheme of arrangement between Network18 and Infomedia18 and their respective shareholders and creditors, as approved by the Hon’ble High Court of Delhi and the necessary approval of Ministry of Information and Broadcasting is being obtained.

0RGHUQ 3KDUPD $SULO

Editorial

Tapping the expanding exports pie he global pharmaceutical market scenario seems set for a clear shift towards generics, albeit the causative factors may vary depending on the present development status of a particular country. On one hand, while emerging opportunities due to patent expiries along with government efforts to expand healthcare insurance as well as cut down healthcare expenses are likely to boost the generics cause in the developed countries, on the other fundamental drivers such as affordability and availability will add traction to the growing footprint of generics in the branded generics developing markets. From a numerical perspective, the global spending on generics is set to rise to $ 430 billion by 2016 from $ 242 billion in 2011, according to IMS Health. In this context, debatable questions remain how will this impact Indian pharma exports and, more importantly, what will be India’s share in this growing pie. A recent report by India Ratings on the outlook for Indian pharmaceuticals for 2013 sheds light on this. As per this sectoral outlook report, top Indian pharma players will continue their good growth momentum at over 20 per cent in 2013, primarily led by exports to the US market, which offers huge near-future opportunities in generics, owing to the impending patent cliff and recently brought in changes in the US healthcare system.

Editorial Advisory Board Ajit Singh Chairman, ACG Worldwide & Head, ISPE

Dr Abraham Patani Past President, IDMA & CMD, Inga Laboratories

Dr Gopakumar G Nair IPR Consultant & Advisor

Dilip G Shah Chairman, IGPA & Secretary General, IPA

Daara Patel Secretary General, IDMA

According to a recent release of Pharmexcil, pharmaceutical exports of Indian companies in 2012-13 are likely to touch ` 75,000 crore – an increase of 25 per cent over the previous year. This growth is quite remarkable considering the competitive scenario and the current geo-economic climate. When one considers the country’s export figures in 2004, which stood at ` 17,000 crore, then the current year’s achievement (as well as over these years) is a tremendous feat! Also, one needs to recognise and appreciate here the contribution of the small and medium enterprises, which constitute a major part of the Indian pharma exports in this growth journey. That said, it is now equally important to take adequate steps so as to reinforce and reinvigorate the new product pipelines for yielding commercial success sooner than later. In this direction, the latest Budget exemption of 15 per cent in investments of more than ` 100 crore to set up plant and machinery augurs well for further capital expansion of the Indian pharma sector. However, it remains to be seen how much of these will translate to green field pharma projects.

Manas R Bastia manas@network18publishing.com

Guest Editorial

Nation taking a cue from Gujarat’s exemplary use of IT-based solutions -governance is the proven tool to generate administrative control, standardisation and efficiency in any system. Nevertheless, customisation for technically intensive regulatory system such as Food and Drugs Control Administration (FDCA), Gujarat, which has 25 circle offices, testing laboratories and addresses the sensitive commodity of drugs and pharmaceuticals, was fairly a voluminous task. At the same time, due cognizance had to be taken for major reforms in the operations and working of international trade, national manufacturing and logistics sectors. FDCA - Gujarat in active association with National Informatics Centre (NIC) as well as encouragement and support from the Gujarat Government initiated the project ‘Xtended Licensing & Laboratory Node (XLN)’ with a view to reduce the delays in granting licences, sample analysis in the laboratory and corrective actions in the case of non-complying reports of various inspections. Generating effective control on the menace of spurious and misbranded formulations has been one of the benchmark expectations through e-governance. Customisation of an approach of e-governance for the activities of

FDCA has been a great challenge and opportunity, given the legacy of administrative excellence of Gujarat FDCA. After getting the web-based software and State Wide Area Network (GSWAN) in all FDCA circle offices, Food and Drugs Laboratory (FDL), Central Medical Store Organisation (CMSO) and Gujarat State Pharmacy Council were connected through a server for storage and retrieval of data. At the outset, compilation and retrieval of information and analysis of information appeared to be a huge task and extremely critical for the precision and credibility of this IT-based solution. Effective communication and training proved to be of great significance and vital to the execution of this process. The entire FDCA and NIC teams worked hard with great perseverance during this phase. The system after customisation and hand over became operational very soon fulfilling the desired objective of speed and control. The concept of ‘SMS’ for communicating with the stakeholders and even public at large as far as information about substandard drugs was concerned has been endorsed as the most relevant, effective and economical solution for developing countries by Dr K Weerasuriya

of WHO at 71 st International Pharmaceutical Federation (FIP) World Congress at Hyderabad. The access to information about availability of blood at various blood banks and stock point and that too - blood group wise - is another benchmark service to healthcare sector and hence public at large. The success of this e-governance exercise of FDCA - Gujarat has received nationwide attention and by the higher authorities such as DCG(I) and other departments interfacing with healthcare sector. Five states, (Maharashtra, Karnataka, Kerala, Himachal Pradesh and Andhra Pradesh), have replicated the ‘Gujarat Model’ of sales licensing software to cater to their functioning, while another six states (Madhya Pradesh, Goa, Tamil Nadu, West Bengal and Chhattisgarh) are planning to replicate Gujarat’s successful experience. The Administrative Reforms and Public Grievances Department of the Government of India and Department of IT have conferred the national award for ‘e-governance for the year 2012-13 Gold Award’ upon Gujarat FDCA. Dr H G Koshia Commissioner, FDCA - Gujarat

0RGHUQ 3KDUPD $SULO

News, Views & Analysis

Bureau of Indian Standards recognises SCHOTT’s expertise in pharmaceutical glass manufacturing The international technology group SCHOTT has been appointed as a member to India’s national standards body. As a new Bureau of Indian Standards (BIS) member, the company will advise CHD-10, a subcommittee of the Chemicals Department, on specifications and guidelines for various kinds of glass manufacturing in India – mainly for pharmaceutical tubing and other applications such as fire-safe glass, household appliances and fibre optics. This allows BIS to tap into SCHOTT’s experience in the areas of specialty glasses, materials and advanced technologies. “It is a tremendous privilege to support BIS in improving glass manufacturing standards in India,” said Sundeep Prabhu, Vice President - Marketing and Sales, Pharmaceutical Tubing, SCHOTT Glass India. “This milestone is another illustration of the outstanding standardisation of product quality and manufacturing processes SCHOTT has achieved in India. Together with BIS, our efforts will benefit Indian consumers as well as industry by ensuring that glass

products are safe, reliable and of highest quality.” Working closely with India’s national standards body, SCHOTT will share its expertise with the aim of enhancing production and testing standards of India’s glass manufacturing industry. SCHOTT has constantly improved its quality standards to accommodate evolving market demands and deliver maximum benefits to its customers. A key global success factor for SCHOTT has been its strong focus on maintaining high quality standards. Company data released recently proves that SCHOTT managed to maintain stringent quality standards in the area of pharmaceutical tubing. “At SCHOTT, we have been setting standards for manufacturing glass tubing with our technical terms of supply. This means we are committed to constantly improve our production process and offer our customers the highest possible transparency and quality assurance,” said Jürgen Achatz, Global Sales Director - Pharmaceutical Tubing, SCHOTT.

Agila Biotech sets up a biotech plant in Malaysia Bio-XCell and Agila Biotech sealed a $ 34.4 million buildand-lease agreement for the establishment of a customised biotech facility located in the Bio-XCell ecosystem in Nusajaya, Johor, Malaysia. The agreement was signed between Rizatuddin Ramli, CEO, Bio-XCell and Dr Anand Iyer, CEO, Agila Biotech (Malaysia), a subsidiary of India-listed Strides Arcolab Ltd. “Agila Biotech is indeed poised to be a major anchor tenant for the Bio-XCell ecosystem and we are extremely

pleased to be able to offer our services and support for this promising project,” said Ramli. Bio-XCell will fund $ 22 million to cover the construction of the building

and part of the equipment. All other related state-of-theart equipment, integration service and testing of this

turnkey project (estimated at $ 13-15 million) will be funded by Agila Biotech (Malaysia) from internal accruals and from external sources. Work on the facility for the end-to-end manufacturing of biologics located on an 8.77 acre plot is expected to start as soon as all necessary clearances and permits have been obtained and all supplemental agreements have been executed. Both parties are aiming for the R&D and manufacturing facilities to be operational by end 2014.

DCGI suggests plan to ensure GMPcompliant drug plant exporters The Drug Controller General of India (DCGI) is drafting a plan that could ensure compliance of domestic bulk drug units exporting pharma products to the European Union. The compliance shall be weighed on the basis of World Health Organization (WHO) regulations. India exports pharma products worth more than $ 13.4 billion every year. API, worth more than $ 1 billion is exported annually to EU countries.

The plans draft suggests that zonal offices for drug regulation shall check API manufacturing processes in India. Once the check is conducted, the reports would have to be sent to EU drug regulatory authority that would certify the practice as WHO compliant. The zonal office team investigating the practices would comprise two officers trained in the quality inspection process. There is a possibility of appointing only a single inspector. An expert in quality

control from regional or central drug testing organisations too could be part of the zonal team. This inspection for checking compliance shall be of a different nature from the conventional checks. If the pharma processes are deemed as compliant with Good Manufacturing Practices (GMP) outlined by WHO, DCGI would give a written nod to the facility in question. The permission would remain valid as a quality assurance tag for three years.

0RGHUQ 3KDUPD $SULO

News, Views & Analysis

Regulatory agencies to give their views on use of clinical data High-profile representatives from regulatory agencies across East Asia will give their country’s perspective on clinical data evaluation for drug approval at Drug Information Association (DIA) Japan’s 7th Annual Conference for Asian New Drug Development in Tokyo, April 15-16, 2013. During a session entitled ‘Perspectives of Respective Regulatory Agencies in Clinical Data Evaluation for Drug Approval,’ Seong-ho

Kim, Director, Pharmaceutical Safety Policy, Pharmaceutical Safety Bureau, Korea Food and Drug Administration, will speak on Korea’s perspective

and Li-Li Su, Pharmacokinetic/ Pharmacodynamic Reviewer, Center for Drug Evaluation, will

speak for Taiwan. The Chinese perspective will be given by Dr Ling Su, Board President, DIA and Dr Yoshiaki Uyama, Director, Regulatory Science Research, Pharmaceuticals and Medical Devices Agency will speak on behalf of Japan. The event to be held at Nakano Sunplaza, Tokyo, aims to provide a forum for exchange of opinions among pharmaceutical industry professionals, academia and the regulatory agencies in East Asia.

Glenmark Generics recalls anti-asthma drug from the US market Glenmark Generics is recalling from the US market multiple lots of Montelukast Sodium tablets (10 mg), used in treatment of chronic asthma and prophylaxis, on ‘offodour’ complaints, according to US FDA. Montelukast Sodium tablets are Glenmark’s generic version of Singulair by Merck & Co Inc, indicated for prophylactic treatment of chronic asthma. A notification issued by US FDA said that Glenmark was withdrawing from the market as many as 591,972 bottles of Montelukast Sodium tablets of both 30 and 90 count on complaints of off-odour. “The recall has been initiated on multiple complaints received from pharmacists and

consumers saying they detected an off-odour, described as moldy, musty or fishy in nature, which has been identified as trace levels of Tribromoanisole (TBA) and Trichloroanisole (TCA)”, said an alert issued by the US FDA. “After initial investigation, the source for the moldy/musty odour has been identified as the presence of trace levels of Tribromoanisole (TBA) and Trichloroanisole (TCA). The presence of TBA and TCA has been observed in HDPE bottles supplied by one of our multiple HDPE bottle suppliers used in the packaging of our Montelukast Sodium Tablets. These compounds are often

used as a preservative in wood-derived packaging storage materials”, Glenmark had said last month. “We have determined that all of Glenmark’s Montelukast Sodium Tablets continue to be safe and effective, and there is no reason to stop taking this medication”, the statement issued by Glenmark had said. This recall is limited to material stored by wholesalers and in stock in pharmacies from the lot numbers and bottles identified above only and all other lots and bottles in use are unaffected and pharmacies may continue to dispense. Glenmark continues to ship unaffected product in alternative bottles, the release said.

In Brief European patent ofﬁce to grant patent for Macrocure’s CureXcell® Macrocure, a biotechnology company developing advanced cell therapy products, has announced that the European Patent Office (EPO) intends to grant a European patent covering companies’s flagship product, CureXcell®. The patent will be officially granted under an application titled ‘Activate Leukocyte Composition’ and will provide patent coverage for CureXcell® in Europe through March 2030. CureXcell is a novel approach to treat hard-to-heal wounds by replenishing the imbalanced inflammatory environment in non-healing wounds with a broad array of functionally active allogeneic immune cells. These cells are superficially injected into the wound bed, once a month, and release the necessary cytokines and growth factors for the wound to heal. “The granting of a European patent for CureXcell is a significant milestone for MacroCure, which fits with our strategy to become a leader in the hard to heal wound treatment market in Europe,” said Nissim Mashiach, President and CEO, Macrocure.

Amid job cuts, AZ appoints Marc Dunoyer as Executive Vice President to head Global Portfolio & Product Strategy AstraZeneca (AZ) has announced the appointment of Marc Dunoyer in the newly created role of Executive Vice President, Global Portfolio & Product Strategy. He will join the company in the second quarter of 2013. He will be responsible for driving business strategy, including business development, M&As, portfolio and product strategies. Marc joins AZ from GlaxoSmithKline (GSK) where, as Global Head of Rare Diseases, he established an integrated global capability in treatments for rare disease R&D through to commercialisation. He is also Chairman of GSK Japan and a member of the Corporate Executive Team. “I am delighted Marc is joining us in this pivotal new role aimed at bringing greater integration across our R&D, commercial and business development activities,” said Pascal Soriot, CEO, Dunoyer AstraZeneca.

0RGHUQ 3KDUPD $SULO

News, Views & Analysis

Pﬁzer’s Zithromax side effects stress the need for novel antibiotics Recent worries over antibiotics losing their effectiveness will only be exacerbated by the FDA’s latest drug safety update, released recently, which stated that the commonly prescribed antibiotic azithromycin can cause abnormal changes in the electrical activity of the heart. Azithromycin, currently marketed as Zithromax by Pfizer, is indicated for a large range of bacterial infections, such as Chronic Obstructive Pulmonary Disorder (COPD), acute bacterial sinusitis, nosocomial pneumonia and certain skin structure infections. The drug’s wide ranging use, improved safety profile and short treatment duration of just five days, compared to the 10 days required by

many competing antibiotics, have made it a popular choice among physicians. These detrimental effects were linked with potentially fatal heart arrhythmias in patients who already exhibited risk factors such as QT interval prolongation, low blood levels of potassium or magnesium and slower heart rates. They were also indicated in patients currently being treated for heart arrhythmias with certain drugs. A study first published in the New England Journal of Medicine in May 2012 showed that patients treated with azithromycin displayed a higher likelihood of developing complications of the heart in comparison to patients treated with amoxicillin, ciprofloxacin, or levofloxacin, or left untreated. The updated

safety information is likely to have been delayed by the manufacturers’ own studies to corroborate this evidence. Dr Brad Tebbets, Analyst covering Infectious Diseases, GlobalData, did not expect the FDA’s announcement to dramatically affect the sales of Zithromax, but stated, “The news could decrease its uptake among patients at risk

of cardiac complications, and these adverse events could also make Zithromax more susceptible to competition from novel antibiotics.”

Some pharmaceutical and biotech companies are attempting to address the rising demand for novel antibiotics, in a pharmaceutical field currently in a state of flux. “Most currently prescribed antibiotics are produced by generic manufacturers, and there is little incentive for pharmaceutical or biotech players to launch new products into the market,” said Dr Ramya Kartikeyan, Senior Analyst covering Infectious Diseases, GlobalData. “The GAIN Act in the US and the innovative medicines initiative in the EU both reflect acknowledgement by governmental, regulatory and research bodies alike of the need to increase research efforts to develop cures against drug-resistant

bacterial infections.” The UK’s chief medical officer, Sally Davies, recently stated that the antibiotics market has stagnated over the past 20 years. “As regulators continue to provide incentives for the development of novel antibiotics, they must also address the issue of antibiotic stewardship both in companies and clinics,” said Dr Tebbets. If novel antibiotics are not used responsibly, resistant pathogens are bound to emerge, which would decrease the sales of the drug and limit treatment options. In addition, Dr Kartikeyan argued that public awareness of resistance is also required to enhance the effects of these initiatives.

Affymax and Takeda announced nationwide voluntary recall of all lots of OMONTYS® injection

Affymax, Inc and Takeda Pharmaceutical Company Ltd recently announced the decision to voluntarily recall all lots of OMONTYS® (peginesatide) injection to the user level as a result of new post-marketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life threatening or fatal. OMONTYS is indicated for the treatment of anaemia due to chronic kidney disease in adult patients on dialysis and is packaged in 10 mg and 20 mg multi-dose vials. The companies have been working actively with the US FDA, which has indicated its agreement with this decision. The companies have also issued a letter to healthcare professionals indicating that no new or existing patients should receive OMONTYS. To date, fatal reactions have been reported in approximately 0.02 per cent of patients following the first dose of intravenous administration. The reported serious hypersensitivity reactions have occurred within 30 minute after such administration of OMONTYS. There have been no reports of such reactions following subsequent dosing, or in patients who have completed their dialysis session. Since launch more than 25,000 patients have received OMONTYS in the post-marketing setting. The rate of overall hypersensitivity reactions reported is approximately 0.2 per cent with approximately a third of these being serious in nature including anaphylaxis requiring prompt medical intervention and in some cases hospitalisation. The companies are actively investigating these cases. In the meantime, dialysis organisations are instructed to discontinue use. The recall is being conducted with the knowledge of the US FDA.

0RGHUQ 3KDUPD $SULO

News, Views & Analysis

Swine ﬂu virus now resistant to current medicine Tamiﬂu Swine flu virus may be now resistant to key medicine Tamiflu, raising fears a new outbreak may be difficult to fight, an Australian research has warned. While just 2 per cent of swine flu (H1N1) strains around the world are resistant to Tamiflu, the Australian research found mutations in all strains of the swine flu that suggest they might be prone to develop resistance. Dr Aeron Hurt from the World Health

Organization collaborating centre for flu research in Melbourne, said the bug appears more prone than other types of flu to developing drug resistance, The Australian reported. Tamiflu resistance develops when an individual under treatment receives the drug to control their symptoms. In most flu viruses, the changes that make the virus resistant to treatment also make it less likely to spread to others.

SPDS to conduct International Convention Disso India 2013 at Mumbai Society for Pharmaceutical Dissolution Science (SPDS) will be conducting its 1 st Annual International Convention Disso India 2013 on May 3 - 4, 2013 in Mumbai. The event will promote introduction of new technology, innovation and would have deliberations on various issues faced related to dissolution. Disso India 2013 event shall witness eminent professionals from the pharmaceutical industry. This event is being organised under the Chairmanship of renowned Dr Vinay G Nayak, PresidentTechnical, Alembic Pharmaceuticals Ltd and the Organising Secretary, Dr L Ramaswamy, Managing Director

- Sotax India Pvt Ltd. The scientific sessions are programmed and executed under the chairmanship of Dr Mangal Nagarsenker, HOD & Professor of Pharmaceutics, Bombay College of Pharmacy, Mumbai. The event shall comprise plenary lecture, poster session, panel discussion and exhibits. Disso India has been specifically designed for all the professionals from R&D,QA and QC as well as the academia. Around 250-300 delegates are expected to participate in this event, which would be first mega event focussing on dissolution. The event will take place at The Lalit, Mumbai. One can log on to www.spds.in for registration.

US FDA approves Navidea’s radioactive diagnostic imaging agent The US FDA has approved Lymphoseek (Technetium Tc-99m tilmanocept injection), a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumour-draining lymph nodes. Lymph nodes filter lymphatic fluid that flows from the body’s tissues. This fluid may contain cancer cells, especially if the fluid drains a part of the body containing a tumour. By surgically removing and examining the lymph nodes that drain a tumour, doctors can determine spread of cancer. Other US FDA-approved drugs used for lymph node mapping include sulfur colloid (1974) and isosulfan blue (1981). “Removal and pathological examination of lymph nodes draining a primary tumour is an important diagnostic evaluation for some patients with breast cancer or

melanoma,” said Shaw Chen, Deputy Director, Office of Drug Evaluation IV, Center for Drug Evaluation and Research, FDA. “To use Lymphoseek, doctors inject the drug into the tumor area and later, using a handheld radiation detector, find lymph nodes that have taken up Lymphoseek’s radioactivity.” The safety and efficacy of this new diagnostic drug were established in two clinical trials of 332 patients with melanoma or breast cancer. All patients were injected with Lymphoseek and blue dye, another drug used to help locate lymph nodes. Surgeons subsequently removed suspected lymph nodes for pathologic examination. Confirmed lymph nodes were examined for their content of blue dye and/or Lymphoseek. Results showed Lymphoseek and blue dye had localised most lymph nodes, although a notable number of nodes were localised only by Lymphoseek.

America’s ﬁrst macrocyclic and ionic gadoliniumbased contrast agent gets US FDA approval US-based medical imaging company, Guerbet, recently announced the US FDA approval of Dotarem® (gadoterate meglumine), a Gadolinium-Based Contrast Agent (GBCA) indicated for intravenous use with magnetic resonance imaging in brain, spine and associated tissues in adult and paediatric patients of 2 years and older, to detect and visualise areas with

disruption of the blood brain barrier and/or abnormal vascularity. Dotarem which is commercialised widely throughout the world since 1989 is the only macrocyclic and ionic GBCA. “This approval is a major milestone for Guerbet, which has a proud history of providing safe and effective contrast agents to patients worldwide,” said Yves L’Epine, CEO, Guerbet Group.

0RGHUQ 3KDUPD $SULO

News, Views & Analysis

Pitavastatin 4 mg superior to pravastatin 40 mg in lowering LDL in HIV patients suggests phase IV study Eli Lilly and Company and Kowa Pharmaceuticals America, Inc recently announced results of a study evaluating the efficacy of LIVALO® (pitavastatin 4 mg) vs Pravachol (pravastatin 40 mg) in reducing Low-Density Lipoprotein Cholesterol (LDL-C) in HIV-infected adults with high cholesterol or dyslipidemia. Study was a phase IV, randomised (1:1), double-blind, double dummy, active controlled, parallel group of 12-weeks period. Dyslipidemia is common in people with HIV infection. HIV-infected adults are at an increased risk for cardiovascular disease due to many factors, including lipid abnormalities. Results showed that after 12 weeks of therapy pitavastatin 4 mg had a significantly greater decrease in LDL-C compared with pravastatin 40 mg (P < 0.001). Those taking LIVALO saw an average drop in LDL cholesterol of 31

per cent, compared with a 21 per cent drop in the group taking Pravachol, a difference that was statistically significant, meaning it was too great to have occurred by chance. “We are pleased that the study objective was met, showing superiority of pitavastatin 4 mg to pravastatin 40 mg on LDL-C reduction in HIV-infected adults with dyslipidemia, and we look forward to further analysis of these data,” said Dr Craig Sponseller, Vice President Medical Affairs, Kowa Pharmaceuticals America, Inc. “In HIV-infected patients with high cholesterol, data such as these represent an important step in understanding lipid management in this immunocompromised patient population,” observed study investigator, Dr Judith Aberg, Director Virology, Bellevue Hospital Center and Director, Division of Infectious Diseases and Immunology, New York University School of Medicine.

Mettler-Toledo launches AXR-P X-ray inspection systems After the success of company’s AXR X-ray inspection systems, MettlerToledo has introduced AXR-P, an improved version of its X-ray technology that is developed to help food and pharmaceutical manufacturers ensure the safety and integrity of a wide variety of packaged products. The device is capable of examining products for foreign body contamination and other quality defects, it offers manufacturers greater quality control to boost production and comply with stringent food safety standards, such as Europe’s International Featured Standards (IFS), to operate in lucrative international markets. The advanced X-ray machine allows brand owners to meet requirements of local legislation, such as the Framework Act on Food Safety introduced in South Korea in 2011, for the inclusion of more rigorous data monitoring on production lines, with storage of product inspection data for both conforming and non-conforming products. The system’s easy-to-use Human Machine Interface (HMI) enables

operators to select and move images into a Graphical User Interface (GUI) for closer examination, as well as compare data from other products in the batch. The AXRP, developed using standardised hardware is also straightforward to service and maintain with increased availability of spare parts and, to boost production line flexibility, additional plug-ins, which allow the inspection of up to 16 different lanes. Other customisation options are available to meet manufacturers’ needs. Jun Zhang, Marketing Associate, Mettler-Toledo Product Inspection, said, “The dynamics of the food and pharmaceutical manufacturing industry are changing due to rising international and regional competition. Boosting production line efficiency, remaining cost-effective and staying ahead of the competition are paramount for manufacturers. Yet these needs must be balanced with ensuring adherence to ever-increasing and changing local and global regulations and standards.”

AZ to focus on biologics, cut several jobs in research, sales and plans relocation of global headquarter by 2016 In a major overhauling British drug giant, AstraZeneca (AZ), has announced loss of 1,600 jobs in R&D and 2,300 job cuts in sales and administration. The company recently denoted the closure of its R&D operation in Alderley Park, Cheshire, UK. The job cuts include reduction in the sales force in Europe, where the company has been hit hard on drug sales. AZ currently employs 51,700 people worldwide, with major operations in the United States, Britain and Sweden. Pascal Soriot, CEO, AZ, also revealed his intention of establishing a new global R&D centre and corporate headquarters in Cambridge in the UK by 2016. “I recognise that our plans will have

a significant impact on many of our people at our sites in Cheshire and London and the surrounding communities. We are fully committed to treating all our employees with respect and fairness as we navigate this period of change. “We remain strongly committed to the North West of England. We are keen to work with central and local government, as well as the business community in the region, to ensure that all practical solutions for the future of Alderley Park are considered in order to support the local economy over the long term,” said Soriot in a statement. The move signifies how US-based MedImmune is gaining power within the company and that AZ wants to focus on biologics.

0RGHUQ 3KDUPD $SULO

News, Views & Analysis

QbD organises ‘The next level in regulatory submissions’ The conference-cum-workshop on ‘QbD: The Next level in Regulatory Submissions’ organised by Indian Pharmaceutical Association (Delhi Branch) was held and successfully completed as planned at the India Habitat Centre on Saturday, March 23, 2013. The event managed by Dr Gaurav Kumar Jain, Joint Secretary, IPA-Delhi Branch and Dr Naresh Sharma, Vice President, IPA-Delhi Branch, was attended by more than 60 participants from various pharmaceutical industries. The conference started with the welcome speech by Dr Farhan Jalees Ahmad, President, IPA Delhi Branch. The welcome speech was followed by an introductory lecture on key components of QbD by Dr Saurabh Arora, Managing Director, Auriga

Welcome speech by Dr Ahmad

Research Labs and Executive Director, Arbro Pharmaceutical Ltd, which set up the base for the conference. Dr Rajeev Mathur, HeadRegulatory of Ranbaxy laboratories Ltd, is a senior in field of regulatory affairs and gave the regulatory perspective of QbD from outlook of Industry. Dr Sachin Gahoi, Assistant General Manager, Mylan Laboratories Ltd is a young

talented scientist who is working on QbD in Mylan Labs and no one better than a scientist working in lab can teach better about the nitty-gritty of QbD in actual practical aspect. Prof Bhupinder Singh Bhoop, Professor, Faculty of Pharmaceutical Sciences at Panjab University is a well-known expert and was the most appropriate authority to impart knowledge about formulation by design.

Lupin gets USFDA approval for new drugs Pharma major, Lupin Ltd, recently announced that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Valsartan and Hydrochlorothiazide tablets USP, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg from the US FDA to market a generic version of

Novartis Pharmaceuticals Corp’s (Novartis) Diovan HCT tablets, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg, respectively. Lupin has already commenced shipping the product. Lupin’s Valsartan and Hydrochlorothiazide Tablets USP is indicated for the treatment of hypertension, to lower blood pressure in patients

not adequately controlled with monotherapy or as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Valsartan and Hydrochlorothiazide tablets USP, 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg had annual US sales of approximately $ 1.7 billion.

Dr Sandip B Tiwari, Techinical Director, Colorcon Asia Pvt. Ltd, gave lecture on Excipients variability in application of QbD, as excipients variability plays a very important part in application of QbD. Bimal K Kesh from Cubic Computing (P) Ltd discussed case studies where statistical software of QbD helps to manage data in effective and efficient manner thus improving process quality. In between presentation a small description about vision of Society for Pharmaceutical Dissolution Science was laid down by Dr L Ramaswamy, Managing Director, Sotax India Pvt Ltd. The presentations of the speakers were followed by the panel discussion session chaired by Dr Albinus M D’Sa, Deputy Director, USFDA, India Office.

16th Pharmaceutical Analysts’ Convention in Mumbai The Indian Drug Manufacturers’ Association (IDMA) and Association of Pharmaceutical Analysts (APA) recently announced that the 16th Pharmaceutical Analysts’ Convention (PAC) 2013 will be held on September 27-28, 2013, at Hotel Hyatt Regency, Sahar Airport Road, Andheri, Mumbai. The main theme for this year is ‘Generics the game changer.’ The event would provide an excellent opportunity for the professionals working in the pharmaceutical industry, R&D institutions, government laboratories and approved testing laboratories, academicians, machine manufacturers, API, excipients and intermediates manufacturers.

Firms selling medicines below government price will have to freeze rates Firms selling essential medicines at less than governmentmandated price caps will have to freeze rates at existing levels, according to the upcoming drug pricing policy. Reports stated that this would constitute a setback to

companies that sell essential drugs at rates below the government-set price. There are reports that the Centre is in the process of expanding the number of drugs whose prices are regulated.

0RGHUQ 3KDUPD $SULO

In Conversation With

I work with one of the best teams in the world on developing ways to help sick people get better Nikunj Sharma nikunj.kumar@network18publishing.com

Tell us about the journey so far. It has been a lot of fun. I work with one of the best teams in the world on developing ways to help sick people get better. I love sitting in meetings with our customers, and listen to how they are working on delivering not just a better return for shareholders but also better products for their patients. I am proud to play a part in this industry. The Indian pharma SME sector is considered a bit apprehensive in adopting security solutions. Is it true or the situation is changing now? When we started offering supply chain services in India in 2007, the Indian pharma sector was bit apprehensive in implementing verificationbased supply chain security services due to the costs involved. But in recent years two things have happened: companies have recognised the value of consumer and stakeholder engagement far beyond supply chain security, and technology has advanced to allow economies of scale across the industry. Companies are beginning to recognise that serialisation is not a commodity market; the hidden costs of manufacturing line shut downs due to poorly developed software are much more expensive than paying a little more in price for a quality software system to control your hardware. We spent millions of dollars on customising software for the Indian market and conducted extensive R&D with our early customers in India to develop excellent software optimised for this market, and this has made a difference in establishing a quality service that works well. How important is drug security in today’s market scenario; and how far India has succeeded in this direction? Globally, there are several reported cases of spurious drugs exported from other nations to different global markets carrying a ‘Made in India’ label. In the domestic market too, consumer confidence needs to be assured through verification technologies. We are closely working with the Indian manufacturing industry to help differentiate their products both globally and here in India.

…says Nathan Sigworth, Co-Founder and CEO, PharmaSecure. The dynamic entrepreneur visualised and realised the dream of secure drug delivery to the consumer’s door step and has been successful in developing a deep-rooted consensus among the Indian manufactures about the pharma security solutions. How do you find the Indian market in comparison with the EU and US markets? In a way, India is ahead. In the US and Europe, the ePedigree and ‘Falsified Medicines Directive’ projects are a long way from implementation. In India, even before the Directorate General of Foreign Trade (DGFT) serialisation mandate came into place, companies had already begun to work with us to implement serialisation-based supply chain solutions. I applaud the Indian government and the industry for starting with manageable solutions that were already in place through the private sector, and working to scale these across the industry in a manageable time frame. But there is something more than regulation that is driving this. For the Indian industry, which has a significant presence in the fast-growing emerging markets, there is an increasing awareness that getting inputs directly from consumers and other stakeholders in the supply chain for the use and movements of products is particularly important. Serialisation unlocks these possibilities. Elaborate on the demand and growth gap in Asia and developed regions. The demand for medicine is growing at much faster rates in South Asia as compared to the US and EU markets, and the future of pharmaceuticals in India, Africa and other emerging economies is bright. Nevertheless, in coming years the industry will need to look beyond a saturated marketing strategy based on doctors. We are helping our customers take leadership by differentiating their products to consumers through opt in mobile health services that come with each product. We are also helping our customers understand discrete consumer behaviour over time. How is PharmaSecure looking forward to tap the unearthed potential of Indian consumers? It is easy to use an example. Last week I went to a hospital in India for a routine checkup and was prescribed some medicines to treat a health condition. After filling my prescription, I verified one of my medicines using the

We stand behind the quality and reliability of our services and are focussed on leveraging serialisation to create real value for our customers through innovative tools. PharmaSecure’s SMS service and was offered a free initial call with a doctor. With some lingering questions I had forgotten to ask the hospital doctor, I opted in. The doctor answered my questions and warned me of a drug interaction. She worked with me to adjust my treatment plan accordingly. Serialisation is by large providing benefits to both the manufacturers and users. We get a lot of feedback from consumers on their use of certain products, and this helps our manufacturing clients better serve their patients.

Key strengths that keep PharmaSecure among the leading players? Two words: quality and innovation. We may not be the cheapest serialisation solution on the market, but we stand behind the quality and reliability of our services and are focussed on leveraging serialisation to create real value for our customers through innovative tools. How do you address post-sales service? We understand that our manufacturers have complex lines and even a small issue can result in big losses. We have on-the-ground teams to respond immediately to sort out any problems, through offsite consultation or on-site visits. We have serialised hundreds of millions of products so far in the Indian market. Where do you see PharmaSecure in the next five years? We would like to see that the pharmaceutical

industry helping their consumers access not just medicines but better health outcomes. We see ourselves helping the industry to accomplish this. Any important/interesting learning you would like to share from life? My brother had a cycling accident in Mussoorie and ended up in a wheel chair. Later on, he made an award-winning film on what it is like to live an active life in India while being on a wheelchair. His message in the film is that if you trust God even bad things in life can be transformed to good. For me, this is a great source of inspiration. How do you maintain a work-life balance? Whenever possible, I ride a cycle from my apartment in Delhi to my office in Gurgaon. I also like to spend time with my family whenever I get the chance.

0RGHUQ 3KDUPD $SULO

Special Focus

Contract manufacturing

Offering cost-effective solutions amid uncertain economic scenario Fluctuation in regional economies and rising regulatory and pricing pressures on the pharma sector have driven the major players’ focus on low-cost regions to fulfil their manufacturing needs. Asia seems to be the preferred destination to address all the issues pertaining to pharmaceutical manufacturing.

Nikunj Sharma nikunj.kumar@network18publishing.com

ontract manufacturing is a strategic alternative for major pharma industries as well as SMEs to address the cost constraints and cater to the needs of emerging biotech companies that lack adequate infrastructure. In a recent pharma workshop, Cambridge Consultants revealed that India’s domestic pharmaceutical sector is expected to grow to $ 55 billion by 2020, and is poised to double its total drug export to $ 25 billion through 2014. The sector will be driven by the technology- and innovation-based operation models. At present, the country houses over 20,000 pharmaceutical companies, which is expected to spur intense competition in the domestic and global markets. The projections clearly steer way for a bigger role of Indian pharma on the World map, with more projects in contract manufacturing being assigned to the Indian SME sector.

Current state of affairs Increasing cost of R&D and drug formulation are leading to higher constraints on pharma players to search for effective measures in order to maximise resources, for instance, outsourcing to Contract Research Organisations (CROs) and establishing new R&D facilities in Asia. The global market of contract manufacturing services is expected to grow at a rate of approximately 10 per cent per year in the near future. The cost constraints on pharma manufacturers have led this sector to look out for low cost and effective resources to manage the expenses and retain the product portfolio. In the recent past Asia has emerged as a hub for costeffective manufacturing services with continuous expansion of its manufacturing capability and up-gradation of the existing units. In the light of this trend, Asia could be the next most-sought destination for pharma contract

manufacturing with potential destinations including China, India, Vietnam, South Korea and Bangladesh. In a PSM conference held recently at Delhi, Lalit Kumar Jain, Chairman Pharma SMEs, said, “SME manufactures produce 85 per cent drugs by volume and 40 per cent by value. Today, over 400 companies in Himachal and Uttrakhand are SME pharma and offer contract manufacturing services to major players. Any small unit need ` 1-1.5 crore to set up a five to six line unit, and the government needs to support the small units in order to maintain quality manufacturing.” Pharma manufactures are increasingly opting for contract research, manufacturing and packaging services to comply with specific requirements, and in quest to reduce expenses and product development cycle while at the same time staying productive and efficient. The production and development strategies of pharma sector are guided by various factors such as delivering simple and efficient solutions as per consumer’s requirement.

Major trends According to a recent report titled ‘Pharmaceutical Contract Manufacturing: World Market Outlook

With growing complexities in manufacturing processes combined with the regulatory constraints, pharma players are devising better collaborative strategies.

2012-2022’; this decade, demand for manufacturing services will rise in all leading countries. Contract Manufacturing Organisations (CMOs) in India and China will experience rising demand for API and generic drug manufacturing. The trend will trigger a demand for manufacturing services of APIs, highly potent APIs, finished dosage, generic APIs, injectable dosage and solid dosage formulations. Global market for contract manufacturing is expected to have the following major trends: Globally, the pharma sector will witness significant trends, which in turn will lead to considerable growth of contract manufacturing segment Major pharma companies will focus on collaboration for expanding in new

market and biotechnology through strategic alliances With major drugs and biologics approaching original patent expiry that will further reduce the profit margins, eventually spurring to the outsourcing of drug manufacturing Introduction of NDDS and new products, pharma SMEs will start developing the contract manufacturing facilities to assist in development of novel drugs The emerging market will witness growth in outsourcing projects due to low-cost services and skilled manpower, for instance, China and India to address the contract manufacturing need of pharmaceutical formulations and bulk drugs. With markets becoming increasingly cost competitive, the low-cost Asian region is the most sought market, especially for manufacturing largevolume products. The trend is forecast to affect the contract manufacturing services sector across the globe.

Growth prospects In the near future, the pharma industry is expected to witness consolidation and expansion, which will offer significant opportunities to the contract manufacturers to form valuable partnerships

with major pharma businesses for delivering manufacturing and drug development services. In addition, expansion in newer market will also benefit contract manufacturing companies apart from enabling them to increase their footprints in regional geographies. Further, the small capacity contract manufacturers will be able to use their expertise in producing drugs for clinical trial projects and compete accordingly. The contract manufacturing business is projected to register growth due to cost management factor, which will also include non-core services such as process and product optimisation in addition to drug manufacturing services. With growing complexities in manufacturing processes combined with the regulatory constraints, pharma players are devising better collaborative strategies. In the past few years, costing pressures have led manufacturing contractors to establish operations in emerging markets such as China, India, South Korea, Singapore and Malaysia. Asia is receiving considerable investment flow, as various western contract manufacturing companies are extending operations in these regions, particularly in China.

0RGHUQ 3KDUPD $SULO

Special Focus

0RGHUQ 3KDUPD $SULO

Special Focus

Green manufacturing practices

Sustainable solutions to drive the future economy In the current global economic turmoil, every industry is experiencing waves of intense pressure. Initially, industries were reluctant in adopting ‘green approach’ but considering the rewards that it offers, companies have recently started re-evaluating their ‘go-green’ strategies. Read on to learn more...

Hardik Ashar

Process Design

hardik.ashar@network18publishing.com

lobally, India is a well-known pharma manufacturing hub and ‘sustainability’ is the latest buzzword in the pharma world. The manufacturing policy adopted last year by the Government of India aims to create 100 million jobs and account for 25 per cent of the GDP by 2022. At the same time, there remain several questions: how long a country can afford to neglect environmental issues in the manufacturing sector?; Why should businesses take the green practices critically?; What is in it for them?; What should they do?

Concept of Green Chemistry

Eco-friendly Materials

Waste Minimisation

Accident Prevention

Current Indian scenario India’s rapid industrial growth has come at the high cost of increasing Greenhouse Gas (GHS) emissions, rising utilisation of resources such as water and increasing waste generation. “A green manufacturing economy is crucial for long-term sustainability,” suggests Prof Chithur Devaraj, Department of Operations, Somaiya Institute of Management Studies and Research. According to a recent report by the Confederation of Indian Industry and Boston Consulting Group, India generates close to 4 million tonne of hazardous waste from industrial and biomedical sources. Today, the country is the fifth largest GHS emitter in the world. During the past 10 years, India’s carbon dioxide emissions have increased more than 150 per cent. To overcome these challenges, the Indian pharma manufacturers need to adopt green approach in manufacturing.

The need to go green By definition, green manufacturing is a method of making a product with minimum waste and pollution. Implementing green manufacturing practices is aimed at substantially reducing air and water pollutants. These goals are met by designing appropriate products and processes. It is an important part of the business. The need is to satisfy legal obligations, saving ‘one earth that we have’ and address economic turmoil. “Globalisation has spurred the pharma industry in India to improve the environmental, health and safety operations,” says Dr R Smarta, MD, Interlink Marketing Consultancy.

Figure 1: Concept of green chemistry

How do we move ahead? Industrial India now recognises the importance of adopting eco-friendly manufacturing practices. MNCs have been going green for years to ensure reduced production cost and environmental sustainability. “Several manufacturers are adopting green chemistry and reducing water-energy consumption so as to lessen their carbon emissions and

environmental sustainability,” he adds. Recent reports suggests that pharma manufacturing in India is catching up with the long-term benefits of green processes to improve corporate image, reduce costs and achieving compliance at the same time. “Companies are implementing plans to minimise waste and enhance energy efficiency,” says Prof Devaraj. However, there is still a long way to go in allied sectors. It is also important to address water consumption and waste generation as big levers of green. It is possible to reduce water consumption by better control of processes, recycling water and embracing new watersaving technologies.

ways to cut down on harmful chemicals by using catalyst or cheaper, eco-friendly solvents,” says Prof Devaraj. “Solvents comprise an estimated 80 to 90 per cent of pharmaceutical waste and make them the major contributor of toxicity in Active Pharmaceutical Ingredient (API) production,” he adds. Some aspects of green chemistry involve catalysis,

Rewards of going green

Green chemistry is in! A green manufacturing economy is crucial for long-term sustainability. Prof Chithur Devaraj Department of Operations, Somaiya Institute of Management Studies and Research

economise operational costs,” affirms Prof Devaraj. Recent studies suggest that going green is a cheaper option and an environment-friendly approach. “Efforts in energy conservation, reduction of GHS and programmes in green chemistry involving solvent reduction and water-based methods in manufacturing are some examples of how companies seek to meet goals in

Researchers across the globe are finding more ecologically prudent ways for the production of pharmaceuticals. ‘Green chemistry’ refers to utilising a set of principles to reduce or eliminate the use/ generation of hazardous substances in the design, manufacture and application of chemical products. Principles of green chemistry involves the design processes to maximise the amount of raw material that ends up in the product; the use of safe, environment-benign substances, including solvents, whenever possible; the best form of waste disposal or not to create it in the first place. “A number of companies are now coming up with economical eco-friendly solvents in place of the hazardous chemicals,” hints Dr Smarta. “Companies are now finding innumerable

such as toluene, methanol, benzene, carbon tetrachloride, chloroform etc. They are hazardous to the environment and life. Many are dangerous to human, demonstrating neurotoxic effects or suspected carcinogens. Residues from these compounds may remain in the finished drug product finding their way into a patient’s body and the environment,” avers Prof Devaraj. Pharmaceuticals are manufactured by chemical synthesis in a step by step mode. “This is a process that requires several reactions, separations and purifications with many intermediate steps. As a rule, each step uses some or other solvent. Streamlining such process and reducing the number of steps and solvents can surely reduce cost thereby improving the economic factor. Moreover, companies are putting considerable effort to switch from conventional batch processing to continuous manufacturing processes. Continuous reactors reduce solvent use by allowing for more heat and enhanced mixing and homogeneity,” he says. “One of the ways companies are becoming cost effective is by adopting green chemistry. It is a highly sophisticated approach taken by the pharmaceutical industry to not just cut down costs but also function more responsibly towards the environment,” affirms Dr Smarta.

Globalisation has spurred the pharma industry in India to improve the environmental, health and safety operations. Dr R Smarta MD, Interlink Marketing Consultancy

solvent replacement, use of renewable feedstocks, waste minimisation, process intensification, improving energy efficiency, better seperation processes, use of safer reactions and chemicals. “Numerous organic solvents are traditionally used in the production of API. This includes toxic and corrosive chemicals

Rewards are tremendous for the manufacturing companies. The government now recognises companies’ efforts of going green and rewards them in the form of tax benefits, incentives and financial help. Going green not only benefits the environment but also impacts the customers and a company’s perception in the market. Dr Smarta says, “One of the major rewards for a company adopting the ‘go green’ mantra could be enhancing the company’s image.” Insurance companies offer better rates to manufacturing companies that are taking steps to go green. In addition, such efforts result in cost saving. “The reality is that if a company can save money on energy, its product costs can go down and its customers will not need to pay as much. In addition, the company can always maintain the same costs and reap great profit on its products thereby helping the stakeholders,” advises Prof Devaraj.

0RGHUQ 3KDUPDÂ&#x2021; $SULO

Special & Focus: Interface

Today, the pharma manufacturing sector wants to comply with different regulatory markets and is more aware of the norms guiding it Pallavi Mukhopadhyay pallavi.mukhopadhyay @network18publishing.com

What are the recent trends in the pharma manufacturing sector? The pharma sector is growing at 25-30 per cent every year. Exports from India have increased and this has lead to increased scope for not just core manufacturing but also pharma machine and equipment manufacturing. With new projects and expansions on the horizon, we see tremendous growth opportunities in this sector. Also, pharmaceutical expos that are being held in different parts of the world in the pharma manufacturing hubs are bringing together buyers and sellers. This in turn has helped the suppliers to reach international market. What types of challenges are being faced by the Indian pharma machinery manufacturing sector? We are facing heavy competition from China as the Chinese pharma equipment and machinery industry is seeing a steady growth in sales volume over the years. Their competitive pricing is a major threat to Indian manufacturers. However, the after-sales services are not up to the mark. On the other hand, India is currently manufacturing good quality products and also provides good after sales services.

â&#x20AC;Śsays Sunil Aggarwal, Director, Airtech System India Pvt Ltd. Here, he talks about the Indian pharma machinery manufacturing sector and its growth opportunities. How do you envision the pharma export industry to grow over the next 5 years? Due to the current focus on exportdriven sales, many pharma companies are in the process of setting up plants in export zones and African countries such as Nigera, Sudan and Uganda. However, the growth in the Indian manufacturing sector has not been up to mark due to the recent wane in demand. Easy procedures for government regulations with better infrastructure and availability of skilled employees would take the manufacturing sector to the next level. Which new technologies has Airtech introduced over a period of time? We are an air solutions provider for HVAC and cleanroom projects with tailor-made solutions for our clients. We have introduced the double skin air handling unit, reverse and horizontal Laminar Air Flows (LAF) static and dynamic pass boxes etc. Today, there is an increasing demand for precision and expertise. All pharma manufacturing units have to comply to USFDA and UKMHRA norms and standards. We are continuously making quality improvements to our products to comply with these standards. We are also involved in validation.

Over the last 10 years, how has the demands of the sector changed? Today, the pharma manufacturing sector wants to comply with different regulatory markets and is more aware of the norms guiding them. They look for energy conservative solutions and automated systems for the ease of compliance with regulatory norms. At Airtech, we have started offering complete turnkey solutions enabling superior execution and timely completion of projects. Most clients are targetting the export market. They want to build facilities as per WHO and USFDA norms. There has been a sudden shift

on focus on quality as there is need to clear several audits. The export trend witenessed recently... Off late, the government is inviting more companies to set up pharma manufacturing plants in Special Economic Zones (SEZs) and providing subsidies and income tax benefits. As demand for pharma units grow and new projects come up, the demand for pharma equipment and machinery also grows. Today, we manufacture 100 per cent export units. Currently, we export 20 per cent of our machinery and are looking to increase this to 35 percent by next year.

0RGHUQ 3KDUPD $SULO

Facility Visit

Venus Remedies Ltd, Baddi

Riding high on innovation Nikunj Sharma nikunj.kumar@network18publishing.com

enus Remedies Ltd, based in Baddi, develops novel research products for critical unmet medical needs in compliance with the global quality standards. The company’s core strength lies in its research products that cater to critical care and super speciality segment, including anti-infectives (Anti-Microbial Resistance (AMR)), anti-cancer, cardiovascular, neurology, pain management and wound care. Pharmaceutical innovations need cognition of disease area and technical insight. While most businesses are limited to primarily focus on any one of these aspects, Venus adopted a business model that possess in-depth research activities, which delivers high impact drugs for patients. Talking about the business model Dr Manu Chaudhary, JMD & Director - Research, Venus Remedies, says, “We are focussed on our own research-based products in the fields of oncology, anti-infective and neurology. We have already made good in-roads into Anti-Microbial resistance (AMR) that we plan to cash-on in the near future. We could foresee the potential of antibiotics reduce due to resistance some 10 years ago and it is the result of our focussed approach that today we have the ‘Super bug’ tackling solutions under patent protection. We would like to enhance our penetration in global markets through strategic alliances on the strengths of product ownership and protection.”

Venus Remedies Ltd is among the few research facilities focussing on Anti-Microbial Resistance (AMR) products globally. The company holds a significant position for developing various solutions in the critical care and super speciality segment, and is committed to explore the requirements of other serious unmet medical conditions.

With a view to deliver effective solutions for life threatening diseases cost effectively, Venus is currently working on a robust pipeline of 25 products that are in different stages of development. Research-driven innovation Venus Remedies owns DSIR recognised research centre in Chandigarh that is continuously engaged in discovering innovative platform technologies to assist in targeted drug deliveries and diagnostics or new drug delivery systems. The company follows a sustainable investment model to support its R&D projects and boost existing capabilities. Emphasising upon the research focus, Dr Chaudhary explains, “The company invests around 16 per cent of total sales turnover in R&D and drug development to ensure updated and fully equipped modern infrastructure to meet the needs of the facilities. Venus Medical Research Centre aims at developing and formulating new and medically required fixed-dose combinations, novel drug delivery systems including target-based delivery of drugs especially for tumours and nanotechnology-based innovation.”

The company also offers expertise in analytical research, molecular biology research and toxicology studies and have marked breakthrough innovations through balancing basic biomedical and translational research for developing medicine in the area of critical illness. Venus has an impressive line of products and continues to thrive with newer launches at times. Recalling the recent product launch by Venus Remedies, Dr Chaudhary informs, “We have launched CSE1034 under the brand name ‘ELORES’ recently. It is a novel Antibiotic Adjuvant Entity (AAE). Designed specifically to target growing bacterial resistance mechanisms, ELORES has a unique profile of action which gives it an edge over all the existing therapies. This unique antibiotic adjuvant entity creates a synergistic effect due to its activity on Acquired Multiple Resistance in Gram Negative Enterococci and Rods (AMRINGER), which stops development and spread of bacterial resistance. Our product is effective against Metallo Beta-Lactamases (MBL) producing pathogens, which are not susceptible to most of the existing antibiotics. It is also unique in its way that it not only kills resistant pathogens (bacteria) but also prevents the spread of resistance.”

Planning for the futre With a view to deliver effective solutions for life threatening diseases cost effectively, Venus is currently working on a robust pipeline of 25 products that are in different stages of development, comprising 12 novel products that have already been commercialised. In addition to this, the company is looking forward to increase its footprint in domestic and global markets through collaborations with other leading players worldwide.

We put in our 100 per cent efforts, dedication and commitment to deliver the best of our services and products to fulfil our objectives and serve the mankind. Dr Manu Chaudhary JMD & Director - Research

“We have engaged two world renowned consultants and are in talks with few well established companies of good repute for out-licensing deals. We are hopeful of materialising a good deal for out-licensing our research products soon in the near future,” she informs. Equipped with a dedicated team of qualified professionals to conduct market surveys and researches to find out the needs and unmet areas in pharma and healthcare sectors, the company is aggressively reaching its goals through strategic future planning and attaining a leadership position in its areas of expertise. Comparing the Indian pharma market with other global markets, Dr Chaudhary points out, “Indian market is different from global

demographies in terms of their regulatory framework. Throughout the world, regulatory systems are becoming more and more stringent to give holistic approach from experiment planning, performance, monitoring, recording, reporting and archiving. Efforts made by National Good Laboratory Practice (GLP) and Compliance Monitoring Authority (NGCMA) are credible but a lot more can be done to improve GLP awareness. Though it is not mandatory to get GLP accreditation in India, some manufacturers have already implemented the concept voluntarily.”

Making a difference to lives Venus Remedies is moving ahead on the basis of innovations, with a focus on developing novel solutions and establishing itself as an innovator company globally. The company has already commercialised a successful product line and is thriving to combat serious or life threatening medical ailments by putting its best resources available including funds, technical expertise, best practices and manpower. Mentioning about the company’s vision and CSR activities, she states, “We firmly believe in our mission that says that we are in the business of preserving and improving human life through innovation and we manufacture medicines for patients, not for profits. Profits follow! Thus, we put in our 100 per cent efforts, dedication and commitment to deliver the best of our services and products to fulfil our objectives and serve the mankind.” The company actively participates in public health programmes on a regular basis that include organising blood donation and eye check up camps at its campus in about every six months.

0RGHUQ 3KDUPD $SULO

Insight & Outlook: Interface

We must have our own ethics committees to have a proper accreditation system in place for global recognition of trial data Nikunj Sharma nikunj.kumar@network18publishing.com

Suggest some measures for ensuring better clinical studies. First, the government must enforce accreditation for all centres performing clinical trials. Second, the doctors who are involved in clinical studies must be accredited, because a good doctor may not be necessarily having good ethics. So, accreditation will bring in accountability for both the research institute and the practitioners, thus in turn improving patient safety. Third point is that all the research institutions must have ethics committees so that any trial being conducted within or through the organisation could be fair and authentic. Furthermore, each member of these committees must undergo adequate training about conducting fair clinical studies. Finally, these members must be accredited by the concerned regulatory authority. The global regulatory agencies will not recognise our data until and unless we provide an ethics committee certification to the studies conducted in the country. Once we will have a proper accreditation system in place, we will have revenue, employment and our clinical trials’ growth will shoot up. What are the major trends witnessed in clinical trials in India in the last decade? Major trend is that MNCs are bringing in more drugs for Cardio Vascular Diseases (CVD), cancer and diabetes mainly, but we are ignoring traditional Indian medicines and our herbal products. No serious studies are being conducted on these products, and also no toxicology study has been performed so far. Currently, they just conduct trial on four to five subjects and send the reports, which are not certified by the ethics committees. Independent investigator must monitor these trials to reap the benefits of these trends. We must have our own ethics committees to have a proper accreditation system in place for global recognition of trial data. Considering that ‘ethics’ is considered a casual term in the India, how critical would you rate ethical practices while conducting clinical trials? The concept of ethics was highlighted in India about five years ago, and since then there has been some progress. Research papers are not accepted in journals unless the data is not certified by ethical committees. India has a significant number of medical and pharmacy colleges and research centers; and controlling unregistered trials is a difficult task. But definitely, we have made progress as now everyone is talking of and is aware about ethics committees and its importance. But given the magnitude of population and subsequent patients, it will take some time for things to fall in place. Apart from the human and animal safety, what steps are being taken for device trials? For device trials we have new stents, which needs to be certified through clinical trials, and most of them contain

…says Prof Ranjit Roy Chaudhury, Chairman - Task Force for Research, Apollo Hospitals Educational and Research Foundations. Here, he discusses some basic measures that can help in addressing the issues related to conducting clinical trials.

drugs. But unfortunately, India lacks a separate medical device regulatory body, despite repetitive recommendation by various groups. Once this demand is met, we can introduce new stents, hip joints and various crucial medical aids. How Clinical Trials Registry – India (CTRI) will help to achieve the goal? Clinical Trials Registry – India (CTRI) will help us because hereon we will know about the trials being conducted in the country as there will be a proper system in place to record the proceedings. Until now, we did not have the system for receiving information about the trials; and if there is no result even in six or eight months time, we can ask about the trials to the concerned departments and that will be the first step. Government of India has passed an order for registration of ethics committees. The second step in this direction will be the accreditation of all these committees by regulatory bodies. All the ethics committees will be accountable for authenticity of the trials data approved by them. The accreditation authority will also possess the right to cancel illegitimate data, if found.

0RGHUQ 3KDUPDÂ&#x2021; $SULO

Projects

New projects and expansion activities are the barometers of industrial growth. These also present business opportunities to service providers like consultants, contractors, plant & equipment suppliers and others down the value chain. This feature will keep you updated with vital information regarding new projects and capacity expansions being planned by companies in the pharma/lifesceinces industry. Bulk drugs manufacturing unit Project type: New facility Project news: Delta Finochem Pvt Ltd planning to manufacture bulk drugs manufacturing unit. Project location: Nashik, Maharashtra Project cost: NA Implementation stage: Planning Contact details: Delta Finochem Pvt Ltd, 121, MIDC, Satpur, Nasik 422 007, Maharashtra Multi-speciality hospital Project type: New facility Project news: B M Birla Heart Research Centre plans to construct a multi-speciality hospital. Project location: Darjeeling, West Bengal Project cost: NA

Manimajra, Chandigarh (U.T.) Tel : +91-172-3933090, 3933094 E-mail : info@venusremedies.com, ib@venusremedies.com Website : www.venusremedies.com

Implementation stage: Planning

Modern vaccine facility Project type: New facility Project news: Shantha Biotechnics Ltd focusses on R&D of generic biologicals, novel therapeutic antibodies, proteins and vaccines.

Contact details: B M Birla Heart Research Centre 1/1 National Library Avenue Kolkata-700027, West Bengal Tel: +91-(033)-24567890/30403040 E-mail: bmbhrc@birlaheart.org

Project location: Andhra Pradesh Project cost: NA Implementation stage: Planning

Manufacturing of drugs Project type: New facility Project news: Venus Remedies announced that it targets gaining returns close to $ 100 million over the next half decade, from the latest drug it launched â&#x20AC;&#x201D; Elores. The drug has been designed to ďŹ ght bacterial infection. India is the ďŹ rst country that has seen its launch.

Contact details: Shantha Biotechnics Ltd 3rd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad, Andhra Pradesh, Tel: +91-(40)-23543010, 23548507 Fax: +91-(40)-23548476

Project location: India Project cost: $ 100 million Implementation stage: Planning Contact details: Venus Remedies Ltd SCO 857, Cabin No. 10, 2nd Floor, NAC

New compression moulding facility Project type: New facility Project news: West Pharmaceutical India Packaging Pvt Ltd, an indirect subsidiary of West Pharmaceutical Services, Incorporated, has started construction of its new compression moulding facility located in Sri City, India. Project location: India

Project cost: NA Implementation stage: Planning Contact details: West Pharmaceutical India Packaging Pvt Ltd 530 Herman O. West Drive, Exton, PA 19341 Tel: +001-610-594-2900 Fax: +001-800-345-9800 Rivastigmine transdermal patches manufacturing unit Project type: Facility expansion Project news: Sparsha Pharma International is planning for capacity expansion of rivastigmine transdermal patches manufacturing unit. Project location: Medak, Andhra Pradesh Project cost: NA Implementation stage: Planning Contact details: Sparsha Pharma International # 8-2-408, D-3, Sri Krishna Apts Road No: 6, Banjara Hills, Hyderabad - 500 034 Andhra Pradesh Tel: 040- 23352581/ 83 Fax: 040-23352880 Email: info@sparsha.com

Information courtesy: www.tendersinfo.com 1, Arch Gold, Next to MTNL Exchange, Poisar, S V Road, Kandivali (W), Mumbai - 400 067, Maharashtra, India t 5FM t 'BY t &NBJM QBSNFFU E!UFOEFSTJOGP DPN

invite that

rewards as well... Dear Reader, â&#x20AC;&#x2DC;Modern Pharmaâ&#x20AC;&#x2122; solicits original, well-written, application-oriented, unpublished articles that reflect your valuable experience and expertise in the pharmaceutical industry. You can send us Technical Articles, Case Studies and Product Write-ups. The length of the article should not exceed 1,200 words, while that of a product write-up should not exceed 100 words. The articles should preferably reach us in soft copy (either E-mail or a CD). The text should be in MS Word format and images in 300 DPI resolution & JPG format.

16-31 Mar c h 2013 I Vol 1 I No 18 I `100

www.modernph

arma.in

Scan this code on your smart phone to visit www.mod ernpharma.in

In Conversa

tion With 13

Dr Ruchi Dass Founder, Healthc ursor Consulting Group

Dr Frank Chairman Heinricht appointed Manageme of the Board of nt of SCHO TT AG

Special Focu

s 14

EU-India Free Trade Agreem ent What is at stake for pharmaceutical s?

Policies & Regulations 17 Indian pharma cy drug stores Need to have a strict regulatory system

Roundtable 19

Is the race for generic s stifling innovat ion in Indian pharma sector?

Agility India controlled fac inaugurates its ďŹ rst tem ility for pha rma near Nh perature ava Sheva

The Superv isory Board of SCHOT T With the Indian AG unanim ously pharma sector with activity appointed bustling and busine logger ss growing per cent per Dr Frank Heinric at 14 are s, and consolidation year, processes set logistics service the need for advanc to the position ht ed superv to be undertaken make signific s has promp under India to set ision of B its new Chairm of ant investm ted Agility Dr Heinric up Pharma gradua the markets. We ents in such ht an The consol warehouse a temperature-controll are looking tes. custom of Management of the Board ed a month idation centre will for its pharm to serve to erâ&#x20AC;&#x2122;s specifi customers our in its meetin witness ly maintenance aceutical c needs February 27, near Nhava value-added g on audit. The and interna 2013. Heinric Mumbai). customer-driv and provide Sheva (near currently the company l India ht (50) is Agility, manag en solutions. end-to-end is seeing a will provid Chairman logistics system es entire lot of potent of the Board of Management services; e the curren starting from collection ial. With of Dr Heraeu include wareho s that t of temperature GmbH. He s Holding market, we surge in generic completed controlled drug distribution, using, expect to physics and a degree in see a lot deman sorting a doctorate d for such and kitting in engineering inclusive servicemore at the Techni shipment cal sizes s as consolidation . The began his professUniversity of Berlin and Against this are going to get bigger. centre was backdrop, Semiconducto ional career at TEMIC inaug pharma supply chain consol rs. After holding by Chris urated idations will as General positions companies Manager and CEO - Asia Price, more value.â&#x20AC;? give pharma Chairman the Integrated With its of Circuits Divisio region. This Pacific latest endeav appointed n, he was is plugging our, Agility 3,000 Chief sq feet, gaps such TEMIC Semico Executive Officer of as the transpo dedica ted problems temperature associated rt In 2003, Dr nductor Group, in 1998. shipments, with small Heinricht joined controlled trouble Holding GmbH warehouse Heraeus extreme temper s that arise due will to ature and of Management.as Member of the Board provide conditions, humidity custom unsuitable He was Chairman ers in West Price inaugur storage facilitie and high costs of the Board appointed ating the facility India with Director in freight operati associated with pharm s optimal 2008. Dr Frankand Labor handli storag a ng facilitie will take office e and Heinricht Agility is weeklyons. The next step shipments on June 1, for This custom s. departures in reefer vehicle 2013. and Antwe to Rotterdam bonded facility of the same s to deliver rp. at CWC Curren Venus located y pharm to respect tly, Agility Logistics ive custom With a Park serves Terminal ers. Mylan, biggies such as Dr marketing signs exclusive Facility, contro CFS, Hind solutioAgilityâ&#x20AC;&#x2122;s cost effectiv Reddyâ&#x20AC;&#x2122;s, Hetero Drugs, e sea freight has all contin ns lled at 18 o with South rights for Potentox Aurobindo C, expect for the pharma sector, With reliabl Africaâ&#x20AC;&#x2122;s Adcoc etc. in case of gency measures in place s to see Agility Venus a times, good e port-to-port transit k Remed ies requirement a healthy growth in the facility power failure. Furthe distribution the and research of such service Ltd, the r, provides comprehensi practices -b Comm enting s. temperature ve knowle pharmaceutic a s e d tracking systemcontinuous develo import and on al company g l o b a l the pment, export regulat dge about s, daily data new is exclusive has accord ions, Agility well marke our roots in Price, said, â&#x20AC;&#x153;We have pharm set to support emerging marke novel antibio ting rights for its its growin a customer tic produc ts and we g base. to South t, Potentox, Africaâ&#x20AC;&#x2122;s pharm Pallavi Mukho giant Adcoc aceutical padhyay k in a deal the compa announced. ny â&#x20AC;&#x153;We are pleased to with Adcoc join hands k and are confident the deal that shall take Ranking among our researc product to h the top its meani by produc ngful stage in South tion volum five globally generic Africa. Adcoc e, the Indian pharmaceutic drugs, exclusive k will have al market marketing the value of India is expected to today accoun for over 10 rights of see reachin its drug exports product in ts $ 25 per cent of the g their expiry South Africa double to billion by production. global drug period of date has peaked over the Simila the end of It continues 15 year. The accord ing . of Indiaâ&#x20AC;&#x2122;s 2014, are rly, at a global product remain under to biggest employ to be one Ministe level there the more generi countr yâ&#x20AC;&#x2122;s patent protec will more than r of Health c pharm till 2025 developers 340,000 Indian ers â&#x20AC;&#x201C; with tion in African Delegate feedba. from other aceutical dedicated to employees territory and is expected nations, includ ck revealed an industry emerging Indian pharm to in excess of 2015 after be launched by mid aceutical industthat the offer low-co ing China,which of $ 22 billion.that is worth has getting due will signific st competition ry still delegates at ant growth approvals.â&#x20AC;? regulatory as well as theÂ Cambridge But senior and for India, opportunities said major local Mumbai Consultants CMD, Venus Â Pawan Chaudhary, , of counte the ongoing global pharma companies have the threat rfeit Remedies worksh Indian drugs. could opÂ said potential Ltd. pharm Andrew Barrett with multin to must embrac aceutical companies , Director, Dr. Reddyâ&#x20AC;&#x2122;s ational pharm compete Techn e innovation Medical ology in companies. annou aceutic techno nces and India, Cambr al Consu Among them, of zoledronic the launch logy if they ltants, said, are to stay compeadopt impact in idge at both a world marke the greatest drive Dr. Reddy acid injection titive from domes faster growth â&#x20AC;&#x153;In order to ts will come â&#x20AC;&#x2122;s Labora those Indian TheÂ Cambridg tic and global level. launched tories has , and on their pharmaceutic zoledronic companies existing succes capitalise attended by e Consultants worksh acid injectio al pharm which adopt (4 mg/5 mL), op, innova a crossâ&#x20AC;&#x201C;section s, Indian n aceutical a bioequivalent techno personnel tions to of senior companies version of from differentiate logy now aim to ZometaÂŽ (zoledr generic products must create true within leading a variety of functio their offerin and make 4 mg/5 mL onic acid) ns compe added-value gs with Indian and them more injection titive both explored the market on in can deliver â&#x20AC;&#x2DC;super-genericsâ&#x20AC;&#x2122;, which domestically question whethe MNCs, globally. March 4, 2013, the US would becom additio This trend and patient the approv r India following for differentiatio s. Innovation nal benefit to is particu al by the leading pharme one of the worldâ&#x20AC;&#x2122; larly n Dr. Reddyâ&#x20AC;&#x2122;s and USFD import are s pharm technology key, and the A. zoledronic aceutical compa ant as Indian 2030? Recent aceutical countries acid 4 mg/5 mL can be recoup required investments by new reports sugges is available injection generic opport nies have fewer domestic ed becaus t Indiaâ&#x20AC;&#x2122;s use vial of in a single produ cts pharmaceutic unities. This concentrate. because have long e medical al sector grow to $ is Techn will Entity the number of New 55 billion lifecyc les. ology has Chemi by significant (NCE) a great role exporter of 2020.Â As a has decline filings to the US cal delivery to in drug extend these high-quality FDA add d over recent lifecycles, value and, the numbe years and r of innova product differe importantly, allow tor drug patent ntiation in s marke a crowded t space.â&#x20AC;?

Cambridge Co Indian pharmnsultants workshop reveals a growth ou tpaces rivals

The final decision regarding the selection and publication of the articles shall rest solely with â&#x20AC;&#x2DC;Modern Pharmaâ&#x20AC;&#x2122;. Authors whose articles are published will be sent a complimentary copy of that particular edition. Published by Network18 Media & Investments Ltd, â&#x20AC;&#x2DC;Modern Pharmaâ&#x20AC;&#x2122; is one of the leading fortnightly magazines exclusively meant for producers and user fraternities of the pharmaceutical industry. Well supported by a national readership of over 80,000 and our strong network of 26 branch offices across India, this magazine reaches out to key decision makers among the Indian manufacturers of pharma products, machinery and allied sectors. Brought out in association with Hong Kong-based Ringier Trade Media Ltd (one of the worldâ&#x20AC;&#x2122;s largest trade publishing houses with more than 200 special interest titles and offices in every major country), it ensures that advertisers are able to promote their products and services across the globe at no extra cost. So get going and rush your articles, write-ups, etcâ&#x20AC;Ś Thanking you, Yours sincerely,

Manas R. Bastia â&#x20AC;&#x153;Disclaimer: Network18 Media & Investments Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the websites of the Lead Managers at www.icicisecurities.com and www.rbs.in. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to â&#x20AC;&#x153;Risk Factorsâ&#x20AC;? in the Draft Letter of Offer. The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the â&#x20AC;&#x153;US Securities Actâ&#x20AC;?), or any state securities laws in the United States and may not be offered or sold in the United States or to, or for the account or benefit of, â&#x20AC;&#x153;U.S. personsâ&#x20AC;? (as defined in Regulation S under the US Securities Act) except in a transaction exempt from the registration requirements of the US Securities Act and in accordance with any applicable U.S. state securities laws.â&#x20AC;?

Senior Editor Modern Pharma Network18 Media & Investments Limited â&#x20AC;&#x2DC;Aâ&#x20AC;&#x2122; Wing, Ruby House, J K Sawant Marg, Dadar (W) Mumbai 400 028 India

D +91 22 3003 4669 T +91 22 3024 5000 F +91 22 3003 4499 E manas@network18publishing.com W www.network18publishing.com

0RGHUQ 3KDUPDÂ&#x2021; $SULO

Tenders

Latest Popular Tenders Brought to you by www.tendersinfo.com BOD : April 16, 2013

BOD : April 22, 2013

UV-VIS spectrophotometer

Loc

: Faridabad, Haryana

Loc

: New Delhi

Org

: Domestic (NCB)

: University Of Agricultural Sciences

Desc : Supply of UV-Vis spectrophotometer BOD : April 12, 2013

NMR spectrometer

Mass Spectrometer (LC-MS/MS)

Loc BT

Org : Department of Atomic Energy Desc : Supply and warranty of compact 60 MHZ

Org

: Bengaluru, Karnataka : Domestic (NCB)

Nano spectrophotometer Org : University Of Agricultural Sciences Desc : Supply of nano spectrophotometer with accessories BOD : April 12, 2013 Loc Bengaluru, Karnataka BT : Domestic (NCB)

Ellipsometer Org : Gallium Arsenide Enabling Technology Centre (GAETEC) Desc : Supply of ellipsometer BOD : April 16, 2013 Loc : Hyderabad, Andhra Pradesh BT : Domestic (NCB)

proton NMR spectrometer reference samples with accessories MNOVA software etc BOD : April 15, 2013 Loc : Mumbai, Maharashtra BT : Domestic (NCB)

Desc : Supply of mass spectrometer (LC-MS/MS)) BOD : April 22, 2013 Loc

: Portugal

: Global (ICB)

X-Ray fluorescence spectrometer

Org

Desc : Supply of tabletting machine

: Mineral Exploration Corporation Ltd (MECL) Desc : Supply of wave length dispersive X-ray fluorescence spectrometer BOD : April 22, 2013 Loc : Nagpur, Maharashtra BT : Global (ICB)

Org

Org : Indian Oil Corporation Ltd (IOCL) Desc : Supply of FTIR spectrophotometer with drift accessories

E Biologia Celular

Tabletting machine

Refrigerated bench top centrifuge FTIR spectrophotometer

: Centro De Neuroci ncias

: All India Institute Of Medical Sciences (AIIMS) Desc : Supply of 18-high speed refrigerated bench top centrifuge

: Ordnance Factory Board

BOD : April 23, 2013 Loc

: Pune, Maharashtra

: Domestic (NCB)

RF signal analyser Org

: Defence Research & Development Organisation (DRDO)

Desc : Supply of RF signal analyser BOD : April 24, 2013 Loc

: Bengaluru, Karnataka

: Domestic (NCB)

Org: Organisationâ&#x20AC;&#x2122;s name; TRN: Tendersinfo Ref No; Desc: Description; DSLD: Doc Sale Last Date; BOD: Bid Opening Date; Loc: Location; BT: Bidding Type Information courtesy: www.tendersinfo.com

1, Arch Gold, Next to MTNL Exchange, Poisar, S.V. Road, Kandivali (W), Mumbai - 400067 Maharashtra, India Tel: t Fax: t Email: parmeet.d@tendersinfo.com

0RGHUQ 3KDUPDÂ&#x2021; $SULO

Event List

N AT I O N A L E V E N T S Pharma Pro&Pack 2013 PHARMA Pro&Pack Expo 2013 will offer an opportunity to expand business in the Indian and international pharma industry. Various industry majors from India and across the world will be present at the Technology Show. The event will help facilitate meetings with clients & prospective customers at one place on one platform thus expanding business to new customers locally & internationally; April 24-26, Bombay Exhibition Centre, Mumbai For details contact: GPE Expo Pvt Ltd Tel: 91-79-40008253 Email: contact@pharmapropack.com Website: www.pharmapropack.com

iPHEX 2013 iPHEX plays a major role in introducing the Indian market to the advanced medicinal products. This show covers up the entire medical industry, starting from hospital services, medicines, pharmaceuticals and surgical sectors. 250 companies have already registered to participate in this event as they think that this podium is best way to reach out to the customers and publicize their brand name; April 24-26, 2013, Bombay Exhibition Center (BEC), Mumbai For details contact: Pharmaceuticals Export Promotion Council Tel: +91-40-23735462/23735466 Fax: +91-40-23735454 Email: sales@iphex-india.com Website: www.iphex-india.com

ADME & Toxicology 2013 and â&#x20AC;&#x2DC;Nanomedicineâ&#x20AC;&#x2122; conference and exhibition The conference will provide attendees with a learning and networking environment where they can share and discuss the latest developments in the field of life sciences. This conference will aim to provide a multidisciplinary approach to tackle the fundamental challenges in this specialty, innovative strategies for testing exposure, and techniques for improving the reliability and accuracy of results. The keynote speakers will give presentations on all areas of nanomedicine backed up by a panel of experts speaking on highly relevant and â&#x20AC;&#x2DC;hotâ&#x20AC;&#x2122; topics such as green nanotechnology, nanomedicine in theranostics besides discussing topics such as novel synthetic approaches in nanomedicine, nano-delivery systems and regulatory and toxicology aspects in nanomedicine; May 30-31 2013, Raddison Blue Plaza, Delhi For details contact: Select Bio Ltd Tel: +44 (0)1787 315110 Fax: +44 (0)1787 315111 Email: enquiries@selectbiosciences.com Website: www.selectbiosciences.com/ conferences/index.aspx?conf=ND2013

PHARMAbiotika Pharmabiotika 2013 is an exhibition with an in built buyer and seller meet which will help one in networking with 10000+ business visitors, 600 delegates and 400+ exhibitors, attending the global exhibition. There are around 30+ thought leaders from across the world sharing their valuable experiential learning in the 3 days

HYDERABAD Andhra Pradesh, May 31- June 3, 2013 Indiaâ&#x20AC;&#x2122;s premier industrial trade fair on products and technologies related to Machine Tools, Hydraulics & Pneumatics, Process Machinery & Equipment, Automation Instrumentation, Packaging & Auxiliaries, IT Products, Electrical & Electronics, Material Handling and Safety Equipment.

For details Network18 Media & Investments Ltd

Ruby House, 1st Floor, J K Sawant Marg, Dadar (W), Mumbai 400 028. R5 &95fhh5iffi5jlkg5R5 295fhh5iffi5jjoo5R5 ' #&95 (! 2*)H( .1),%gn*/ &#-"#(!8 )'

conference. The event will help in meeting the potential customer requirements mapping for developing new trade leads and analysing the exhibiting plan and execute trade objectives, September 16-18, 2013, Mahatma Mandir Convention & Exhibition Center, Gandhinagar For details contact: Human Crayon Management Services Pvt Ltd Tel: +91- 120 â&#x20AC;&#x201C; 6528801 Email: info@crayon4.com Website: www.pharmabiotika.com

Indian Pharma Expo The Indian Pharma Expo 2013 will be one of the a unique pharma events inIndia that will serve as a perfect platform for pharma entrepreneurs andinvestors, eager to be a part of the pharmaceutical business through franchisee and distributorship opportunities in the India pharma market. The two-day expo will bring together drug manufacturers, pharma companies and the largest suppliers and distributors of pharma products under one roof in order to facilitate the exchange of ideas for better growth of the industry; September 20-21, 2013, Pragati Maidan, New Delhi

For details contact: UBM Medica India Pvt Ltd Tel: +91-22-66122600 / 66122673 Fax: +91-22-66122626 Email: info.india@ubm.com Website: www.ubmindia.in

34th International Conference on Bioscience, Biochemical and Pharmaceutical Engineering The main focus of this conference is to bring scientists, researchers and scholars together to exchange and share experiences and research results about bioscience, biochemical and pharmaceutical engineering, and discuss the practical challenges encountered and the solutions adopted. The conference will deal with topics such as bioscience, biochemical and pharmaceutical engineering, affective neuroscience, astrobiology and more; December 5-6, 2013, Sheraton, Bengaluru For details contact: World Academy of Science Engineering and Technology Tel: +44-782-4879405 Website: www.waset.org/ conferences/2013/bangalore/icbbpe/

I N T E R N AT I O N A L E V E N T S 8th Annual Drug Discovery Chemistry Conference This is one of the few events specifically for medicinal chemists working in pharma & biotechnology sectors. It is focused on discovery & optimisation challenges of small molecules. Nobel Laureate will give the keynote address. The meeting will discuss Anti-Inflammatories, Fragments, Macrocyclics, Kinase Inhibitors, PPI & GPCRs. The event offers opportunities for scientists to create unique programs according to personal interests; April 16-18, 2013 Hilton San Diego Resort & Spa, San Diego, CA, USA For details contact: Cambridge Healthtech Institute Tel: +1 781-972-5400 Fax: +1 781-972-5425 Email:chi@healthtech.com Website: www.drugdiscoverychemistry.com

Pharmaceutical Research Conference for Pharmacy Students & Young Graduates Themed â&#x20AC;&#x2DC;Meeting of the inquisitive minds: translating research into realityâ&#x20AC;&#x2122;, PRC 2013 is set to be the arena for pharmacy students & young graduates to showcase research & interact with other young researchers to ignite interest & exchange ideas. The conference will provide an environment for pharmacy students to present their research work and share their knowledge. Participants

can present and discuss the newest developments and breakthroughs in the field of pharmacy. It will set base for more interaction between pharmacy students and young graduates; May 11-12, 2013 Cyberjaya University College of Medical Sciences, Selangor, Malaysia For details contact: Faculty of Pharmacy, Cyberjaya University College of Medical Sciences Email: secretariatprc@cybermed.edu.my Website: http://prc2013.weebly.com/

18th Edition of FCE Pharma FCE Pharma will be held to promote pharmaceutical industry. At the event, exhibitors will get an opportunity to showcase their innovative products and services such as equipment, services, logistic, processes, quality control, outsourcing, analysis, laboratorial, process equipment, valves, automation and technology. The main aim of FCE Pharma will be to bring together world renowned companies related to raw material and packing. The event will provide the visitors with the latest developments and trends. The event attracts visitors and exhibitors from all over the world; May 14-16 2013, Transamerica Expo Center, Sao Paulo, Brazil For details contact: NĂźrnbergMesse Brasil Tel: +55 (11)-3205-5000 Fax: +55 (11)-3205-5070

Email: fcepharma@nm-brasil.com.br Website: www.fcepharma.com.br/en/

International Congress of Toxicology 2013 The theme for the conference is â&#x20AC;&#x2DC;From Basic Science to Clinical and Environmental Outcomesâ&#x20AC;&#x2122;. This conference encompasses novel approaches and technologies being used to properly assess the safety, toxicity, and risk for human health. The scientific programme will consist of keynote/distinguished lectures, symposia, workshops, round table discussions, debate and poster sessions. This meeting will provide attendees with ample opportunities to exchange the ideas and to launch collaborations; June 30-July 4, 2013, Coex, Seoul, Korea For details contact: ICT XIII Secretariat Tel: +82-2-557-8422 Fax: +82-2-566-6084 Email: ict@ict2013seoul.org Website: www.ict2013seoul.org

Pharma Trials World Korea 2013 Pharma Trials World Korea 2013 is where pharma companies, trial sponsors, regional and international CROs and clinical trial sites gather to strategise in accelerating clinical development, accessing emerging markets, enhancing clinical operations through effective offshoring and outsourcing in Korea; July 8-11, 2013, Korea

For details contact: Terrapinn Pvt Ltd Tel: +65 6222 8550 Fax: +65 6226 3264 Email:enquiry.sg@terrapinn.com Website: www.terrapinn.com

3rd International Conference on Environmental, Biomedical and Biotechnology 3rd International Conference on Environmental, Biomedical and Biotechnology is sponsored by the Asia-Pacific Chemical, Biological & Environmental Engineering Society. It is one of the leading international conferences for presenting novel and fundamental advances in the fields of environmental, biomedical and biotechnology. It also serves to foster communication among researchers and practitioners working in a wide variety of scientific areas with a common interest in improving environmental, biomedical and biotechnology-related techniques; August 24-25, 2013, Royal Hotel, Singapore For details contact: Asia-Pacific Chemical, Biological & Environmental Engineering Society Tel: +86-28-86528465 (China Branch) Email: cebb@cbees.org Website: www.icebb.org The information published in this section is as per the details furnished by the respective organiser. In any case, it does not represent the views of Modern Pharma.

0RGHUQ 3KDUPD $SULO

Event Report

8th Nutra India Summit

Providing impetus to the surging nutraceutical market Pallavi Mukhopadhyay pallavi.mukhopadhyay @network18publishing.com

he 8th Nutra India Summit was held amid a thriving intellectual gathering of individuals from the global nutraceutical, pharma, functional foods and dietary supplement industry. The Summit was held in Mumbai across a span of 4 days during March 13-16, 2013 and was inaugurated by Satej Dnyandeo Patil, Minister of State for Home, Rural and Food & Drug Administration (FDA), Maharashtra. The event witnessed several sessions addressed by 65 acclaimed speakers and attended by 500 plus delegates. Participants from 20 countries including China, Japan, Singapore, Brazil, Canada, USA, New Zealand, Germany, Switzerland, France, Poland, and the Netherlands from 300 organisations were seen at the event.

Focussing on further growth With today’s mantra being ‘invest in healthy living’, this market has visions of growing to one of India’s key markets in the future. The growing evolution of both the pharmaceutical and nutraceutical sector was discussed during the event. According to reports, the nutraceutical industry is poised to be a $ 4 billion industry by 2015. While the nutraceutical industry is deemed to be a promising sector, its need for convergence with the booming pharma sector was highlighted. Sandeep Gupta, Group VP - BD & Strategic Initiatives/ Innovation, Geltec Pvt Ltd, said, “Today, the pharmaceutical industry is still the frontrunner. However, with the recent spate of acquisitions, companies such as Reckitt and Pfizer will soon enter the Indian supplement market alongside Amway, which is already adding value and creating awareness about this segment. Today, emerging lifestyle diseases need to be addressed by nutraceuticals as prevention is more important than cure. Self-regulation will be the key to success for the nutaceutical industry.” Adding to this, Dr R K Sanghvi, Chairman, Nutraceutical & Medical Subcommittees - IDMA, said, “Pharma can help impart critical knowledge about nutraceuticals to the doctors as many are still unaware of it. With proper understanding and education, this sector will witness a steady growth over the next few years.” Going forward, the nutraceutical and pharmaceutical industry should enter a strategic relationship in order to cater to the changing customer needs.

Allied activities In addition to the seminars and conferences, various other activities were arranged on the sidelines by the organisers. The Morning Mantra session at the 8th Nutra India Summit included talks by several keynote speakers. Further, the CEO Summit focusing on the theme ‘Regulation, Innovation and Validation of Claims’ also brought together various important industry leaders. Nutra Excellence Awards recognised the contribution

With the nutraceutical industry seeing a steady rise in growth figures and consumer demand, the 8th Nutra India Summit set a good platform for knowledge sharing and business meetings alike. This report takes a closer look at the happenings at the event this year.

Representatives of British Biologicals receiving award from Dr V Prakash, Chairman, 8th Nutra India Summit

of important personalities and organisations. Nutraceutical bigwigs such as Amway, Sami Labs, British Biologicals and more were awarded under various categories The InterlinX Partnering Tool helped organise nearly 140 B2B meetings. An ‘Expression of Interest’ was signed between Brazilian Society of Food Science & Technology, International Society for Nutraceuticals, Nutritionals and Naturals (ISNNaN) & Nutra India Summit. NuFFooDS, The Health & Food Expo, saw around 50 exhibitors from India and overseas including corporate, scientific labs, wellness organisations and attracted around 3,000 visitors. The Expo also witnessed the launch of Metagenics in India by Heal Wellness. Free sampling of products took place in the Expo, making it a suitable platform for product launches and sample distributions. The NuFFooDS Expo also organised seminars conducted by the Indian Dietetic Association, Mumbai Chapter on better health for better living.

0RGHUQ 3KDUPDÂ&#x2021; $SULO

Book Review Essential Microbiology for Pharmacy and Pharmaceutical Science

Editors: Geoffrey Hanlon & Norman Hodges

Understanding microbiology is an integral part of pharmaceutical sciences, both for developing molecules against microbes and also in ensuring sterile drug formulations. This book gives an excellent overview into the concepts of microbiology relevant to a pharmacist or a pharmaceutical scientist. The book comprises three major parts, the first of which deals with the very basics of microbiology. The first part devotes chapters to bacteria, fungi, protozoa and viruses in brief. Each chapter elaborates on the structure, clinically relevant functions and medical targets for therapy. The second part goes on to describe the various infections caused by bacteria, fungi, protozoan and viruses. The initial chapter in part 2 about infection basics and immunity aims at a revision of old and new concepts, followed by a chapter dedicated to the various types of antibiotics available today. Part 3 is of more direct interest to the industry, as it deals with bioburdens, sterility testing, identification of organisms, antiseptics and disinfectants, design of sterile processes and facilities, and the use in medicine production. The book has a good flow and uses simple language but is no way a complete text. However, what it lacks in text, it makes up in colourful flow charts, diagrams and actual photographs. This is a good book for pharmacy students to revisit their basic concepts about microbiology.

Price: ` 2,250

Publisher: Wiley â&#x20AC;&#x201C; Blackwell Distributor: Wisdom Book Distributors, Hornby Building, 1st Floor, 174, D N Road, Mumbai 400 001, Tel: 022 2207 4484/6631 8958, Telefax: 022-2203 4058 Email: thadam@vsnl.com

Handbook of Injectable Drugs 17th Edition Editor: Lawrence A Trissel Price: ` 19,000

Publisher: American Society of Health â&#x20AC;&#x201C; System Pharmacists Distributor:Wisdom Book Distributors, Hornby Building, 1st Floor, 174, D N Road, Mumbai 400 001, Tel: 022 2207 4484/6631 8958, Telefax: 022-2203 4058 Email: thadam@vsnl.com

One of the â&#x20AC;&#x2DC;legendaryâ&#x20AC;&#x2122; books in the pharmaceutical industry, this 17th edition on injectable drugs adds in new monographs to make this an up-to-date reference guide. A must have for everyone in the pharmacy space or the industry as a whole, the book comprises 332 monographs of injectable formulations arranged alphabetically. Each monograph is organised into multiple subheadings. The first â&#x20AC;&#x2DC;productsâ&#x20AC;&#x2122; details the various dosage sizes, strengths, volumes and packing in which it is supplied. It also stresses the point that formulation information must play a significant role in deciding selection of drug by healthcare providers. â&#x20AC;&#x2DC;Administrationâ&#x20AC;&#x2122; deals with the various routes by which the drug can be administered. Another major heading is â&#x20AC;&#x2DC;stabilityâ&#x20AC;&#x2122; of the formulation. â&#x20AC;&#x2DC;Compatibilityâ&#x20AC;&#x2122; with other injectable drugs and infusions is of paramount importance especially when administering through Y â&#x20AC;&#x201C; sites or three ways. This is described in a tabular format for major infusions used commonly. The book concludes with an appendix devoted to parenteral nutrition formulae and their constituents. The book is a plethora of information, which is impossible to recollect at a momentâ&#x20AC;&#x2122;s notice, but can easily be retrieved from this book. A must have text for all healthcare personnel, pharmacists, pharmaceutical scientists among others. Reviewer: Dr Mandar Kubal, Director, Infectious Diseases & Pulmonary Care Pvt Ltd

Yes! I would like to subscribe to Modern Pharma for... Â&#x2026; 1 year (24 issues) `1200/Fill all details in capital letters Name : Mr/ Ms. :..................................................................................................................................................... Organisation : ......................................................................................................................................................... Please send my copy to : Â&#x2026; Residence

Â&#x2026; Office

Â&#x2026; Factory ( Kindly tick only one )

Mailing Address : .................................................................................................................................................... City : ............................................................................ State : ................................................................................. Pin : ......................................................................................... 16-3 1

Mar c h

2013 I Vol 1 I No 18 I `100

Telephone : (O) ..................................... (R) ......................................... Mobile : ................................................. www.mod ernp

harma.in

Scan this your smartcode on phone to visit www.mo dernpha rma.in

E - mail : .........................................................Subscriberâ&#x20AC;&#x2122;s Signature : ..............................................................

In Convers

ation With

Dr Ruchi Dass Founder, Health Consulting cursor Group

Dr Fran k Heinricht Chairman appo Managem of the Boar inted ent of SCHOTT d of AG The

13 Special

Focus 14

EU-India Free Trade Agreement What is at stake pharmaceuti for cals?

Policies & Reg Indian pharm ulations 17 acy drug stores Need to have regulatory a strict system

Roundtab le 19

Agility Ind controlled ia inaugurate s its ďŹ r facility for pharma st temperatur e near Nh ava Shev a Is the race stiflin

for generi cs g innova Indian pharm tion in a sector ?

Supervisory Board of SCHOTT AG unani With the Indian pharm appointed mously with activi a sector Dr Frank bustli per cent ty and business Heinricht per year, growing ng loggers, to the logistics the need at 14 and conso position services are set Dr Heinri for of its new lidation India to has prom advanced cht to Chairman set supervision be undertaken processes of Mana warehouse up a temperaturepted Agility make signif gement of the Board The conso of B Pharm under the February in -controlled icant invest customers for its pharm markets. a 27, 2013. its meeting ments a mont lidation centre graduates. on currently We are aceutical in such hly maint Mumbai). near Nhava looking custo the ChairmHeinricht (50) will witne audit. to serve Sheva of Mana enanc is Agility, ss value merâ&#x20AC;&#x2122;s specific an of the logistics gement to our needs manages (near end-t The company e and intern Board of Dr systems GmbH. al India -added customer-d and provi o-end entire include that He comp Heraeus Holdi services; will provide is seeing riven soluti de warehousin collection physics ng leted starting a lot of distributio a and the curre g, of temp potential. ons. from at the Techn a doctorate in degree in n, sortin erature and kittin market, nt surge in engineering With controlled g generic began his ical University we expec consolidati g. The of Berlin demand drug professional t and Semiconduc for such to see a lot on centr career was shipment more inclusive e inaug as Gener tors. After holdin at TEMIC services by Chris urate d al Against sizes are going g positio as the Integr Manager and this ns to get bigge Price CEO Chairman chain conso backdrop, pharm ated Circui r. Asia Pacifi , appointed of ts a suppl region. companies lidations will Chief ExecuDivision, he was TEMIC This 3,000c give pharm y more value sq feet, Semiconduc tive Office With its a .â&#x20AC;? r of In 2003, latest endea temperature dedic ated is plugg Dr Heinr tor Group, in 1998. ing Holding vour, Agilit controlled GmbH as icht joined Herae problems gaps such as of Mana Member us the transp y warehouse will shipments, associated of gement. ort Chairman He was the Board with troubles customers p r o v i d e extreme small appointed of the Director temperaturethat arise due in West Price inaugu India condi in 2008. Board and Labor to tions, with optim and rating the will take Dr Frank handling office on and high unsuitable storag humidity facility al stora June 1, 2013.Heinricht facilit costs associ e facilit ge and freight This custo ies. operations. ated with pharmies shipments Venus m bond at CWC Agility is in reefer ed facilit of the marketing signs weekly deparThe next step a vehicles y locate same Terminal Logistics Park and Antw for tures to with Sout rights for exclusive Facility, CFS, Hindd With Agilit to respective to delivery Rotterdam has all pharma erp. Currently, customers. h Africaâ&#x20AC;&#x2122;s Potentox contingencycontrolled at solutions yâ&#x20AC;&#x2122;s cost effect Venu s Agility biggies Adcock 18 oC, in case ive sea serves Mylan, for the measu freigh Hetero such as Dr Reddy of expects pharma r e s e a r Reme dies Drugs, the facili a power failurres in place to sector, Agilit t Ltd, ch With reliab â&#x20AC;&#x2122;s, Aurobindo the requiremensee a healthy pharmaceut- b a s e d y times le porttemperaturety provides e. Further, growth etc. t of such globa exclusive ical company continuou Com tracking services. in the and , good distri to-port transi has accor l marketing systems, s devel ment ing bution t comprehen novel antibi d daily on pract opme rights sive import data for its and expor knowledge ices our roots nt, Price, said, the new to South otic product, about is well in emerg t regula â&#x20AC;&#x153;We have giant Adco Africaâ&#x20AC;&#x2122;s pharm Potentox, set to tions, Agilit ing mark pharma support ets and announced.ck in a deal the aceutical customer its grow y we company base. ing â&#x20AC;&#x153;We are Pallavi Mukhopadh with Adco pleased to join yay the deal ck and are confid hands product shall take our ent that Ranking in South to its meaningfuresearch among by produ the top exclusive Africa. Adcock l stage five global ction volum pharmaceuti ly gener e, product marketing rightswill have the cal marke ic drugs Indian for over in South of the , India t today the value period 10 Africa is expec accounts of production. per cent of of over the $ 25 billionits drug expor ted to see remain 15 year. The produ global drug It contin reach under of ts doubl Indiaâ&#x20AC;&#x2122;s ing ct will ues by the till 2025 accor ding patent end of e to Similarly,their expiry date prote more than biggest emplo to be one to 2014, Minister is expec in African territo ction has peake yers â&#x20AC;&#x201C; the are more at a global ted to of Healt with dedicated 340,000 Indian d. coun tryâ&#x20AC;&#x2122;s ry and be launc of 2015 h. level there Delegate employees hed by developers generic pharm after in excess to an industry feedback mid Indian approvals.â&#x20AC;? getting due that is worth aceutical from nation pharmaceut revealed that regulatory delegates of $ 22 billion said Â Pawa has signif CMD, the offer s, including other emerging . at ical indus n Venus Mumbai theÂ Cambridge But senior China low-cost Remedies Chaudhary, and majoricant growth oppor try still Consultants pharma competition,which will as well Ltd. Indian tunities, local comp as have Dr. Redd pharmaceut workshopÂ for India the of count the ongoing anies could yâ&#x20AC;&#x2122;s anno must embra said ical global threat, erfeit drugs with multi potential of zoledronic unces the to comp technology ce innovation companies Andr . national launch comp Dr. Redd acid inject and if they are pharmaceut ete Techn ew Barrett, Direc ion at both to stay comp adopt impacanies. Among ology tor, Medi launched yâ&#x20AC;&#x2122;s Labo rator ical a dome them, in t etitive Cons in stic and cal India, TheÂ Cambri the greate from thoseworld markets (4 mg/5 zoledronic acid ies has Cambridge global level. st drive ultants, said, dge Consu mL), a bioeq attended injection faster growt â&#x20AC;&#x153;In order companies Indian pharmwill come version by a crossâ&#x20AC;&#x201C; ltants works uivalent on their of hop, personnel to h, and aceutical generic section innovation which adopt 4 mg/5 ZometaÂŽ (zoled from a of senior pharmaceutexisting succe capitalise ronic acid) within mL inject s to differ technology produ market leading variety of functi ion in ical comp ss, Indian entiate now aim on explored India ons comp cts and anies their the approMarch 4, 2013, the US make the questi n and MNC must offerings to create true them would s, globa etitive both on wheth more added Dr. Redd val by the following become with â&#x20AC;&#x2DC;super dome er India lly. This can delive yâ&#x20AC;&#x2122;s zoled leading one of USFDA. -genericsâ&#x20AC;&#x2122;, -value trend for stically and is partic 4 mg/5 ronic pharm the world which patients. r additional mL is availa acid inject 2030? Recen aceutical â&#x20AC;&#x2122;s pharm ularly impo differentiation ion use vial Innovation count benefit ble in a rtant as t repor are key, of conce domestic to ts sugge ries by new aceutical comp and single Indian and the ntrate. anies generic required technology can be grow to pharmaceutical st Indiaâ&#x20AC;&#x2122;s opportunit have fewer investment recouped because $ 55 billion sector produ ies. significant will Entity the numb er of New This is Techn cts have because medi s exporter by 2020.Â As (NCE) cal long Chemical a has ology has of highfilings to lifecy cles. declin quality delivery a great the US role in FDA the numb ed over recen to drug add value extend these t years er of innov and lifecy and, impo ator drug product patents rtantly, cles, differentiat allow market ion in space.â&#x20AC;? a crowd ed

Cambrid ge Consult Indian ph ants work arma grow shop reve th outpac es rivalsals

http://e

shop.in

fomedia

18.in

Please find enclosed cheque/DD no ................................................................................................................... drawn on (name of bank) .................................................................................................................................... dated .....................................................or ` ........................................................................................................... favouring Network 18 payable at Mumbai. OR charge my Â&#x2026; VISA Â&#x2026; Mastercard Â&#x2026; American Express Card No. : ........................................................................... Card Expiry Date : .................................................. DOB ................................................................................... CardHolderâ&#x20AC;&#x2122;s Signature : ........................................

Modern Pharma, Subscription Department, Network 18, A Wing, Ruby House, JK Sawant Marg, Dadar West, Mumbai 400 028. 4EL s &AX E-mail: customersupport@network18publishing.com or customercare@network18publishing.com Terms & Conditions : Your subscription will start from the next available issue. Network 18 will take utmost care to dispatch the copies safely. Network 18 does not take the responsibility of any postal delays and damaged copies dispatched. For more information contact Network 18 subscription department. Above rates are valid in India only.

0RGHUQ 3KDUPD $SULO

Products

Looking For A Specific Product? Searching and sourcing products were never so easy. Just type MPH (space) Product Name and send it to 51818 eg, MPH Laboratory software and send it to 51818

Powder coating booth

Aerosol photometer

The primary purpose of the powder coating booth is recollection of oversprayed powder for reuse. The booth also acts towards containment of the oversprayed powder within its confines, thereby preventing powder spillage in the work area. The powder coating booth is designed to accommodate manual or automatic applicators on either one side or in a back to back fashion. The booth is engineered to be stationary or mounted on wheels or trolleys to reduce the cleaning time in case of high volume production plants.

The latest version, Model 2i, is used for leak testing of HEPA filters. The upstream aerosol mass concentrations are displayed in actual mass concentration values of micrograms per litre (μg/l). Other features include user settable Aerosol Noise Suppression (ANS) which allows for more stable aerosol measurements when poor mixing is present, three unique data report functions – continuous, monitoring and summary modes, large 4.3 " LCD display, thermal printer option to meet documentation requirements and USB output.

Intech Surface Coating Pvt Ltd Pune – Maharashtra Tel: 020-2292 2350, Mob: 09822000625 Email: projects@intechfinishing.com Website: www.intechfinishing.com

Compact cooling centrifuge These compact cooling centrifuge model CM-8 Plus is suitable for routine sample analysis in medical, hospital, pathology and institutional laboratories. With a wide choice of rotor heads and adaptors, this unit is truly versatile. The brushless induction motor with frequency drive ensures gentle start and has CFC–free refrigeration system. It has motor overload protection, gas hinge to prevent falling of door and emergency lid lock release. Remi Elektrotechnik Ltd Mumbai – Maharashtra Tel: 022-40589888 Mob: 09820627422 Email: sales@remilabworld.com Website: www.remilabworld.com

Water bath This equipment offers superior temperature accuracy, rugged construction with minimum heat loss. Pump circulation flow gives maximum uniformity of temperature. Water bath are used for incubation in water media, immersion requirements, external circulation to spectrophotometer, jacketed glassware, etc. They are also used for heating of solution / liquids in a jar flask and many other applications in the field of research, development, production and quality control. Sarbi Mumbai – Maharashtra Tel: 022-26049538 Email: sarbi1@vsnl.com Website: www.sarbi.com

MeasureTest Corporation Mumbai – Maharashtra Tel: 022-2202 7982 Email: sheesh@mtnl.net.in Website: www.measuretest.com

Universal supermixes Universal supermixes, iTaq universal SYBR green supermix and the iTaq universal probes supermix, are compatible with any real-time PCR instrument. These products deliver robust performance and enable users to obtain high-quality data across all real-time quantitative PCR (qPCR)

applications. Both are 2x concentrated, ready-to-use reaction master mixes and are made with a proprietary optimised buffer formulation for maximum sensitivity and reproducibility. The SYBR green supermix is optimised for dye-based qPCR and contains SYBR green I dye, whereas the probes supermix is formulated for probe-based qPCR (simplex or duplex). Their key benefits include broad dynamic range and sensitivity, optimised buffer formulation, ability to overcomes challenging duplex qPCR and antibody-mediated hot-start DNA. Bio Rad India Pvt Ltd Gurgaon – Haryana Tel: 0124-2398112/13/14, Mob: 09350047686 Email: sales.india@bio-rad.com Website: www.bio-rad.com

0RGHUQ 3KDUPD $SULO

Products

SIP and CIP system

Strip seal

PTFE-lined valves

This SIP and CIP system has a CIP module which is activated by a PLC and complies with 21 CFR part11 of USFDA. This system is equipped with a positive valve and an open/close indicating sensor and is provided with a supply pump and a return pump with auto draining system. It comes with complete automatic operation and has user definable parameters. The system displays on-line view of process and fault messages. Its features include: restart of cycle from the same stage where stopped due to power failure or fault, printing of process parameters, storage of parameters, etc. The manufacturing vessel is available in portable-or stationary-type according to CGMP and ASME standards.

The pilfer-proof strip seal prevents im ita tio n of branded and quality products and helps control adulteration and pilferage. It has a tamper-evident locking action in a one-piece construction and is precision moulded from durable, tough, high strength, weather resistant engineering Nylon 66 material. The strip seal is lightweight, corrosion-effective, economical and cost-effective. The company’s name/logo can be permanently hot-stamped on it. This seal is used in pharmaceuticals industry, bulk drugs, airlines baggage, postal department, chemical industry, bank lockers, courier bags, containers, drums, etc.

Fluoropolymer FEP, PFA, PTFE-lined

Vyanktesh Fabricraft Pvt Ltd Nashik – Maharashtra Tel: 0253-6602691/2383603 Email: vyankteshen@yahoo.co.in Website: www.vyankteshfabricraft.com

Novoflex Marketing Pvt Ltd Kolkata – West Bengal Tel: 033-22260513, Mob: 09903163634 Email: sales@novoflex.co.in Website: www.novoflexgroup.com

Before taking deliver y of any machine, one must This take trials of the product for a short time. and cy efficien t’s produc the ine will help determ effectiveness.

SGI/WCB/SS pipes, valves and fittings are manufactured using technical know-how and raw material for appropriate application of the resin. They have low co-efficient of friction, chemical inertness, excellent weathering resistance, zero water absorption, are non-toxic, non-inflammable, selfsealant and approved by international food and drugs regulatory authorities. Supremo Line & Control Ahmedabad – Gujarat Tel: 079-22205282, 22205181 Email: supremoproduct@gmail.com Website: www.supremoproduct.com

Molecular weight detector Flexible screw conveyor

Syringe pumps This syringe pump has a touch screen interface and a new clamping mechanism which holds a single syringe (glass, plastic, or stainless steel) from 0.5 μL to 60 mL. The large color display allows the user to see all the operating parameters. Syringe sizes, flow rate, volume delivered and the elapsed time are easily displayed. When used with check valves, the pump draws fluid from a reservoir while the opposite side dispenses fluid. After dispensing the usersettable volume, the pump automatically switches direction and dispenses from the other side while the just-consumed side is being refilled. Full-metal chassis provides noise isolation and anti-vibration features for increased reliability. Cole-Parmer India Mumbai – Maharashtra Tel: 022-67162222 Email: vinita.singh@coleparmer.in Website: www.coleparmer.in

The helix flexible screw conveyor has only one moving part. The conveyor can be disassembled in less than 20 minutes for cleaning and maintenance. It can achieve lengths of up to 80 ft long. A wide range of auger styles and sizes ranging from 2 to 8 inches in diameter is offered. The product meets stringent standards and has USDA certifications. It is one of the most economical conveyors and can be used in many applications. Hapman Systems Pvt Ltd Vadodara – Gujarat Tel: 0265-2517505 Email: info@hapman.in Website: www.hapman.in

Sysmac automation platform

The lyophiliser is used for pharmaceuticals, biotechnology and allied industries. Lyophilisation is the preferred drying process, for heat labile substances or where any physical, chemical or enzymic changes are detrimental to the products and its applications. Sublimation of frozen ice directly in the form of vapour under high vacuum is the basis of lyophilisation process. The system offers optimal ﬂexibility in programming the recipe to suit a wide variety of products. The drying chamber is designed for full vacuum and overpressure of 2.5 bar.

It is a new automation controller NJ-Series t h a t integrates motion, sequencing, networking, RFID tracking and vision inspection. It comes with new software - sysmac studio - that includes configuration, programming, simulation and monitoring and a fast machine network - Ether CAT - to control motion, vision, sensors and actuators. The NJ-Series incorporates an Intel processor with fan-free operation. It delivers a true integrated development environment (IDE). Sysmac studio also offers an advanced 3D simulation environment to develop and test off-line motion profiles such as cams & complex kinematics. Intellectual property (IP) can be safely secured using 32-character passwords.

Machinfabrik Mumbai - Maharashtra Tel: 022-25555596 Email: machinfabrik@vsnl.com Website: machinfabrik.com

Omron Automation Pvt Ltd Mumbai - Maharashtra Tel: 022-42288400 Email: in_enquiry@ap.omron.com Website: www.omron-ap.co.in

Lyophiliser

Zetasizer μV is a versatile size and molecular weight detector that can be added to any system to boost experimental productivity by maximising information ﬂow from a single experiment. It is a dual integrated light scattering system with particular value for protein characterisation. It uses dynamic light scattering to secure precise molecular size measurement while at the same time offering static light scattering for absolute molecular weight measurement. It allows the characterisation of discrete samples with only 2 μL of material. The instrument can be added to any protein SEC system to bring absolute molecular size and molecular weight capability to the chromatography experiment, and avoid the need to calibrate the column.

Malvern Aimil Instruments Pvt Ltd Mumbai - Maharashtra Tel: 022 - 39183596, Mob: 09867368075 Fax: 022 - 39183562 Email: soloni.gosalia@malvernaimil.com Website: www.malvernaimil.com

Cold cabinets The REMI cold cabinets are designed for bio sample storage. The intelligent controller helps maintain temperature in case of sensor failure. The data stored in PC server with Lan connectivity can be monitored on any PC with password authentication. The machine is filled with PUF insulation to eliminate void pockets and the powerful fan motor is for forced air circulation to maintain uniform conditions inside the chamber.

Sharayu Sawant (Director-Shruti Flexipack Pvt Ltd)

Remi Elektrotechnik Ltd Mumbai – Maharashtra Tel: 022-40589888 Mob: 09820627422 Email: sales@remilabworld.com Website: www.remilabworld.com

Stability chamber Stability chamber is designed as per international standards to meet requirement of all registration authorities. This equipment offers superior temperature accuracy, humidity accuracy, minimum heat loss, better air flow for maximum uniformity of temperature and humidity. Stability testing is an integral part of formulation development. It helps to generate information, which permits well-considered proposals to be made for the shelf life of drug substances products and recommended storage condition. Stability data is required to be submitted as part of the dossier submitted to the regulatory agencies for licensing approval. Sarbi Mumbai – Maharashtra Tel: 022-26049538 Email: sarbi1@vsnl.com Website: www.sarbi.com

Pneumatic conveyor The MiniVac pneumatic conveyor comes with a complete integral blower, which eliminates the need for an expensive plant air or a separate compressor. The regenerative blower increases operating efficiency. It lengthens filter life and maximises performance with a standard reverse pulse jet filter cleaning system that keeps the filter clean and at optimum operating efficiency. The standard size access doors allows for easy filter replacement in less than five minutes without the use of any tool. The compact and integral blower eliminates the need for air piping and makes installation easier. Hapman Systems Pvt Ltd Vadodara – Gujarat Tel: 0265-2517505 Email: info@hapman.in Website: www.hapman.in The information published in this section is as per the details furnished by the respective manufacturer/distributor. In any case, it does not represent the views of

Modern Pharma

0RGHUQ 3KDUPDÂ&#x2021; $SULO

Marketplace

Heartbeat of the Healthcare Industry MODERN MEDICARE is a GHÃ&#x20AC;QLWLYH PDJD]LQH RQ KHDOWKFDUH HTXLSPHQW WHFKQRORJ\ 7KLV PRQWKO\ PDJD]LQH SURYLGHV WKH ODWHVW WUHQGV LQ GHSWK YLHZV DQDO\VHV RQ KHDOWKFDUH VHFWRU Modern Medicare LV WUHDWHG DV D UHOLDEOH VRXUFHERRN ZKLFK IDFLOLWDWHV VRXUFLQJ GHFLVLRQV LQ WKH PHGLFDO IUDWHUQLW\ Â² KRVSLWDOV VSHFLDOW\ FOLQLFV SDWKRORJ\ ODEV QXUVLQJ KRPHV DQG GRFWRUV

For further enquiry, write to: b2b@network18publishing.com OR Call us on: 022- 3003 4650 To source product from this magazine SMS: MM (Space) Product Name to 51818

Scan this code on your smart phone to visit www.modernmedicare.co.in

0RGHUQ 3KDUPD $SULO

30 List of Products & Advertisers Looking For A Specific Product? Searching and sourcing products were never so easy. Just type MPH (space) Product Name and send it to 51818 eg, MPH Laboratory software and send it to 51818 Product

Pg No

Product

Pg No

Product

Pg No

Product

Pg No

Access control ....................................................... 29

Deep freezer ....................................................... 9,10

LVS .........................................................................BIC

Roll compactor ....................................................... 17

Acoustic enclosure ............................................11, 23

Dissolution testing.................................................... 7

Lyophiliser ............................................................... 28

Roots blower .....................................................11, 23

Aerosol photometer................................................ 27

Door interlock system............................................ 29

Metal doorset ......................................................FIC

Separation and purifying solutions................... 15

Air circuit breaker.................................................BIC

Drives/Invertor ......................................................BIC

Modular clean room ............................................FIC

Servo.......................................................................BIC

Air shower controller ............................................. 29

Dry van pump ..................................................11, 23

Molecular weight detector..................................... 28

SIP and CIP system ................................................ 28

Air sterilisation.......................................................BC

Dynamic pass box ................................................FIC

Oven .................................................................... 9,10

Stability chamber .................................................... 28

Ambient air monitor - Envirotrack and Sampler .....6

Electric actuator and gripper.............................. 13

Pass box inter-lock system .................................. 29

Strip seal .................................................................. 28

Barcode patient ID band ..................................... 29

Electronic gas monitor............................................. 6

Photostability chamber ....................................... 9,10

Syringe pump.......................................................... 28

Capsule ﬁlling ....................................................... 17

Exhibition - Plastivision 2013 ............................... 27

Physical testing .......................................................... 7

Sysmac automation platform................................ 28

Chemical gas detector .............................................. 6

Fire alarm .............................................................. 29

PLC .........................................................................BIC

Tablet press............................................................ 17

CIP/SIP system and efﬂuent treatment plant ....... 8

Fire resistant door.................................................FIC

Pneumatic coveyor ................................................. 28

Tablet press accessory............................................. 17

Clean room door ..................................................FIC

Flexible screw conveyor ......................................... 28

Powder coating booth ............................................ 27

Three parameter display ........................................ 29

Cleanroom equipment and accessories ............... 19

Fltration ................................................................... 15

Printer ...................................................................... 29

Tubing product ....................................................... 17

COD analyser and digester ..................................... 6

Guided compact pneumatic cylinder ................ 13

Proﬁle nano ﬁlters for CMP applications ........... 15

Turnkey solutions for Biotech and Pharma industry ... BC

Cold cabinet ............................................................ 28

High-purity water treatment systems for injectibles.8

PTFE-lined valve..................................................... 28

Universal supermixes........................................... 27

Colloid mill ............................................................. 17

Human-Machine Interface (HMI).....................BIC

Pump..................................................................11, 23

Vacuum booster pump .................................. 11, 23

Comminuting mill ................................................. 17

Humidity chamber .............................................. 9,10

Punch and dies ....................................................... 17

Vacuum system .................................................11, 23

Compact cooling centrifuge.................................. 27

HVAC and MEP ....................................................BC

Pure water and steam process................................. 8

Virosil pharma .......................................................... 3

Compact pneumatic cylinder ............................... 13

International exhibition for pharma and healthcare ..25

Rapid endotoxin detection system..................... 29

Walk-in humidity chamber ............................. 9,10

Contactor and motor starter...............................BIC

Ionizer ...................................................................... 13

Refrigrated compressed air dryer ......................... 13

Walk-in incubator ............................................... 9,10

Container sterilisation...........................................BC

Label ....................................................................... 29

Reinforced silicone hose ........................................ 17

Water bath ............................................................... 27

Content uniformity testing ..................................... 7

Laminar air ﬂow unit...........................................FIC

Reverse laminar air ﬂow ......................................FIC

XRX 20 bioreactor system .................................. 15

Advertiser’s Name & Contact Details

BC-Back cover, BIC-Back inside cover, FIC-Front inside cover

Advertiser’s Name & Contact Details

Pg No

AIRTECH SYSTEMS (I) PVT.LTD. T: +91-22-28592275

Advertiser’s Name & Contact Details

Pg No

Advertiser’s Name & Contact Details

EVEREST BLOWER SYSTEMS T: +91-11-45457777

IPHEX 2013-Pharmexcil T: +91-22-24938750

Pg No

PRAJ INDUSTRIES LTD T: +91-020-22905000

E: sales@airtechsys.in

E: info@everestblowers.com

E: sales@iphex-india.com

E: info@praj.net

W: www.airtechsys.in

W: www.everestblowers.com

W: www.iphex-india.com

W: www.praj.net

ALL INDIA PLASTICS MFRS ASSOCIATION 27 T: +91-22-28217324

EVEREST BLOWERS T: +91-11-45457777

KARNAVATI ENGINEERING LTD T: +91-2764-241464

E: info@everestblowers.com

E: info@karnavationline.com

E: india@reynders.com

W: www.plastivision.org

W: www.everestblowers.com

W: www.karnavatiengineering.com

W: www.reynders.com

FABTECH TECHNOLOGIES INTL PVT LTD T: +91-22-61592900

E: india.customercare@crl.com

E: sales@fabtecheng.com

MACK PHARMATECH PVT. LTD. 9, 10 T: +91-2551-230877 E: sales@mackpharmatech.com

W: www.criver.com

W: www.fabtecheng.com

W: www.mackpharmatech.com

Chemical & Process World T: +91-022-30034650

GMP TECHNICAL SOLUTIONS PVT LTD FIC T: +91-22-66083790

E: cpw@network18publishing.com

ELTECH SERVICES PVT LTD T: +91-40-27759895

MITSUBISHI ELECTRICAL INDIA PRIVATE LIMITED BIC T: + 91-020-27102000

SANOSIL BIOTECH PVT LTD T: +91-22-22872295 W: www.sanosilbiotech.com

SOTAX INDIA PVT LTD T: +91-022-42950191

E: info@mei-india.com

E: sotaxindia@sotax.com

W: www.gmptech.net

W: www.MitsubishiElectric.in

W: www.sotax.com

Pall India Pvt. Ltd T: +91-80-40164131

E: devgupta@sanosilbiotech.com

E: prashant@gmptech.net

GREAT EASTERN IMPEX PVT LTD T: +91-011-2347431/32

REYNDERS LABEL PRINTING INDIA PVT LTD 13 T: +91-149-3305400

E: pvi13@plastivision.org

CHARLES RIVER T: +91-80-25588175

Pg No

UNIPHOS ENVIROTRONIC PVT LTD 6 T: +91-22-61233500

E: sales@eltechservices.com

E: sales@geipl.com

E: pratyusha_ghosh@ap.pall.com

E: gasdetection@uniphos.com

W: www.eltechservices.com

W: www.geipl.com

W: www.pall.com

W: www.uniphos-she.com

BC-Back cover, BIC-Back inside cover, FIC-Front inside cover

Our consistent advertisers

RNI No: MAHENG / 2008 / 27125, 3RVWDO 5HJG 1R * 10' 3RVWHG DW 3 & 6WJ 2IÂ¿FH *32 0XPEDL 2Q WK WK 2I (YHU\ 0RQWK 'DWH 2I 3XEOLFDWLRQ WK 2I (YHU\ 0RQWK